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A Multiparametric MRI for the Classification
and Grading of Prostate Cancer
Natalie Korn
Abstract
Prostate cancer is one of the most common diseases in men worldwide, however only a small
percentage of men with prostate cancer have aggressive cancer, and most men diagnosed
with focal disease have indolent disease with low risk of progression compared to the risks
associated with treatment. There is a current, pressing need to differentiate between aggres-
sive and indolent prostate cancers in ways that are minimally invasive and not damaging
to patients. This dissertation proposes the multiparametric MRI of the prostate, with its
inherent non-invasive technique void of harmful radiation, as a solution. However, the cur-
rent multiparametric MRI of the prostate is not widespread, due to lingering artifacts and
ambiguous results in some acquisitions. In this work, we provide improvements to pulse
sequence software, acquisition hardware, and image-processing software for the multipara-
metric MRI of the prostate. Additionally, we introduce hyperpolarized carbon-13 imaging in
patients as part of a phase 2 clinical trial, with the unique ability to quantify tissue energetics
as a signature of prostate cancer’s abnormal metabolism.
viii
Table of Contents
1 Practical aspects of prostate MRI: hardware and software considera-
tions, protocols, and patient preparation 4
1.1 History, Environment Hardware and Patient Preparation . . . . . . . . . . . 5
1.2 Anatomic T1- and T2-weighted Imaging . . . . . . . . . . . . . . . . . . . . . 10
1.3 Diffusion-weighted Imaging . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
1.4 Dynamic Contrast-enhanced Imaging . . . . . . . . . . . . . . . . . . . . . . 20
1.5 1H MR Spectroscopic Imaging . . . . . . . . . . . . . . . . . . . . . . . . . . 25
1.6 13C MR Spectroscopic Imaging . . . . . . . . . . . . . . . . . . . . . . . . . 29
1.7 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
2 A Reduced-FOV Excitation Decreases Susceptibility Artifact in Diffusion-
weighted MRI for Prostate Cancer Detection 33
2.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
2.2 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
2.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
2.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
3 Distinguishing Inflammation from Low-Grade Prostate Cancer in the
Peripheral Zone of the Prostate 51
3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
3.2 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
3.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
3.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
4 Multi-element, Multi-nuclear Endorectal Coil for Development of a 13C,
1H-Multiparametric Magnetic Resonance Imaging Exam of the Human
Prostate at 3T 66
4.1 Background and Significance . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
4.2 Prototype Design and Simulation Results . . . . . . . . . . . . . . . . . . . . 72
4.3 Future Directions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
ix
5 The Rate of Hyperpolarized [1-13C]Pyruvate to [1-13C]Lactate Conver-
sion Distinguishes High-Grade from Low-Grade Prostate Cancer in Pa-
tients 82
5.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83
5.2 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86
5.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90
5.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97
Bibliography 104
xList of Figures
1.1 A Multiparametric MRI of the Prostate . . . . . . . . . . . . . . . . . . . . . . 6
1.2 Oblique axial T2 with and without an ERC . . . . . . . . . . . . . . . . . . . . . 9
1.3 T1 Decay over 60 Seconds . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
1.4 T2 Decay over 60 Seconds . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
1.5 2D and 3D Axial T2-weighted Images of the Prostate . . . . . . . . . . . . . . . 15
1.6 Stejskal-Tanner Pulsed Gradient Diffusion Model . . . . . . . . . . . . . . . . . 16
1.7 Full- and reduced-Field-of-View DWI . . . . . . . . . . . . . . . . . . . . . . . . 20
1.8 Common Enhancement Curves in DCE . . . . . . . . . . . . . . . . . . . . . . . 24
1.9 1H-MRSI in Cancer and Contralateral Benign Tissue . . . . . . . . . . . . . . . 27
1.10 13C-MRSI in Murine Models . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
2.1 Distortion Scores from Sample Patients . . . . . . . . . . . . . . . . . . . . . . . 39
2.2 A Typical Distortion Pattern . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
2.3 A Distortion Case from Contamination Aritfact . . . . . . . . . . . . . . . . . . 43
3.1 Decision Tree Classifier . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
xi
3.2 Signal intensities in Inflammation, Low-grade Prostate Cancer, and Normal Pe-
ripheral Zone Tissue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
3.3 Representative Inflammation and Low-grade Prostate Cancer in a Patient . . . . 60
3.4 DCE MRI Time Signatures for Inflammation, Low-grade Prostate Cancer, and
Normal Peripheral Zone Tissue . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
4.1 Semi-automatic Segmentation of the Prostate . . . . . . . . . . . . . . . . . . . 74
4.2 Proposed Coil Array Geometry . . . . . . . . . . . . . . . . . . . . . . . . . . . 75
4.3 Receive Field Profile Simulation . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
4.4 Solid Copper Inductive Coupling Prototype . . . . . . . . . . . . . . . . . . . . 78
4.5 2D Simulation of Oblique Axial Field Map over Prostate Sizes . . . . . . . . . . 79
5.1 A patient with Aggressive, High-grade Prostate Cancer . . . . . . . . . . . . . . 93
5.2 A Patient with Indolent, Low-grade Prostate Cancer . . . . . . . . . . . . . . . 94
5.3 Box Plot of the Maximum Values of Carbon Parameters . . . . . . . . . . . . . 95
5.4 A Patient with Bilateral Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . 96
5.5 ROC Analyses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97
xii
List of Tables
2.1 Distortion Scoring Statistics Table . . . . . . . . . . . . . . . . . . . . . . . . . 42
2.2 Contrast-to-Noise Ratio Comparison . . . . . . . . . . . . . . . . . . . . . . . . 44
4.1 Prostate Size Distributions in 847 Patients . . . . . . . . . . . . . . . . . . . . . 79
5.1 Clinical Presentation of Patients in a Phase 2 Clinical Trial of Carbon Imaging
of Prostate Cancers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92
5.2 Carbon Parameters in Normal Peripheral Zone, Low-grade, and High-grade Prostate
Cancers. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94
1Introduction
Prostate cancer is one of the most common types of cancer in American men. Although the
prevalence is high in the US and abroad, the mortality rate for prostate cancer is proportion-
ally low and the risk of lowering quality of life with therapeutic interventions is relatively
high. Clinicians and hospitals are faced with increasing numbers of prostate cancer patients
and treatment decisions, and the need to improve diagnostic tools.
The multiparametric MRI (mpMRI) exam of the prostate is a powerful noninvasive tool
for the detection and staging of prostate cancer. First popularized by the widespread com-
bination of high-resolution T2-weighted imaging with functional diffusion-weighted imaging
(DWI), a number of versions of the prostate mpMRI exam now exist in major hospitals
around the world.
In Chapter 1, we present the current state of the multiparametric MRI prostate exam.
We present the practical aspects of acquiring an mpMRI including T1-weighted and T2-
weighted imaging to assess anatomy, diffusion-weighted imaging (DWI) to detect changes in
tissue cellularity, dynamic contrast-enhanced imaging (DCE) to semi-quantitatively analyze
perfusion and tissue cellularity and structure, proton spectroscopic imaging (1H-MRSI) to
measure differences in steady state metabolite levels, and carbon-13 spectroscopic imaging
(13C-MRSI), with the potential to probe rates of metabolic reactions in patients. We further
present considerations in hardware, patient preparation, and standardization.
In Chapter 2, we present a solution to the susceptibility artifact common in DWI of the
2prostate. DWI is the most common functional imaging sequence used in prostate cancer
mpMRI exams. However, susceptibility artifact from the adjacent rectum can distort the
peripheral zone of the prostate, where 70% of prostate cancers are located. Our solution is
a pulse sequence modification using a reduced Field-of-View excitation, based on a sequence
developed to decrease similar artifact in the spinal column. By using a 90◦, 2D spatially-
selective, echo-planar RF pulse to limit the excitation in the phase-encode direction suffering
from susceptibility artifact, we show significantly less distortion in the resulting apparent
diffusion coefficient (ADC) maps.
In Chapter 3, we develop a model to distinguish inflammation in the peripheral zone of
the prostate from low-grade prostate cancer based on DWI and dynamic contrast-enhanced
imaging (DCE MRI). Inflammation is a common confounder of prostate mpMRI because of
its similar signature to low-grade prostate cancer on ADC maps produced from DWI. Using
post-radical prostatectomy whole-mount data labeled with Gleason scores of cancers and
regions of chronic inflammation, we construct a decision tree model that distinguishes 80%
of regions of inflammation from regions of low-grade prostate cancer, and make recommen-
dations for inclusion in the American College of Radiology’s Prostate Imaging Reporting
and Data System (PI-RADS).
In Chapter 4, we propose an improvement in the acquisition hardware used for acquiring
an mpMRI by creating a dual-tuned, multi-element endorectal coil to facilitate the trans-
lation of hyperpolarized 13C-MRSI into the clinic. Hyperpolarized metabolic imaging offers
real-time quantification of metabolic rates, correlating changes in cellular metabolic path-
3ways, such as aerobic glycolysis and the tricarboxylic acid (TCA) cycle, to the presence,
aggressiveness and response of cancer to therapy. Hyperpolarized 13C MRI data of the
prostate needs to be acquired rapidly due to the relatively rapid relaxation of the hyperpo-
larized state (the T1 relaxation rate of the
13C nuclei) and also requires 3D coverage of the
prostate to be clinically useful. We aim to take advantage of the increased speed of parallel
imaging, which requires the construction of a multi-element endorectal RF coil optimized for
prostate imaging. We present simulated fields of several potential coil geometries, based on
the Bio-Savart law, and find a three-element longitudinal design to provide increased imaging
acceleration factor, increased field strength in the peripheral zone, and sufficient coverage of
the anterior prostate.
In Chapter 5, we introduce findings from the first phase 2 clinical trial of hyperpolarized
13C-MRSI in the human prostate. We discuss incorporating acquisition design from murine
models and the phase 1 clinical trial at UCSF, and add pharmacokinetic modeling to quantify
the rate of metabolic conversion of [1-13C]pyruvate to [1-13C]lactate, kPL. We find that hy-
perpolarized 13C-MRSI can distinguish metabolically-aggressive high-grade prostate cancer
from indolent low-grade prostate cancers, based on correlation with whole-mount pathology
after radical prostatectomy.
4Chapter 1
Practical aspects of prostate MRI:
hardware and software considerations,
protocols, and patient preparation
Abstract
The use of multiparametric MRI scans for the evaluation of men with prostate cancer has
increased dramatically and is likely to continue expanding as new developments come to
practice. However, it has not yet gained the same level of acceptance of other imaging tests,
partly due to lack of standardization in both the scan environment and imaging protocol
design. In this chapter, we describe several practical aspects of prostate MRI that may
facilitate the implementation of new prostate imaging programs or the expansion of existing
ones, beginning with an overview of the scan environment before focusing on the imaging
protocol.
51.1 History, Environment Hardware and Patient
Preparation
Multiparametric magnetic resonance imaging (mpMRI) of the prostate combines anatomic
with functional and physiological assessment of the gland, and encompasses various se-
quences, including T1- and T2-weighted MR imaging, diffusion-weighted imaging (DWI),
dynamic contrast-enhanced (DCE) MRI, and possibly including proton magnetic resonance
spectroscopic imaging (1H-MRSI)[1] [2] as shown in Fig. 1.1.
In addition to structural data, the mpMRI exam offers information about the microscopic
mobility of water, biochemical characteristics, neovascularity, and cellular structure of the
prostatic tissue. Since these characteristics are different for malignant and benign tissues,
high-resolution mpMRI provides valuable data that helps characterize the extent and bi-
ological behavior of prostate cancer, and is increasingly being used to assist patients and
clinicians to make more informed decisions on treatment [3] [4] [5].
The mpMRI exam can offer a comprehensive assessment of the prostate using metrics
that can be tailored according to the patient’s clinical need, with particular attention to
the patient’s treatment history [7]. The imaging metrics most relevant to diagnosis may
change for imaging patients after radiation [8], focal brachytherapy [9], hormone treatment
and/or surgery [10]. Implants associated with abdominal and pelvic comorbidities—such as
hip replacements or lumbar fusions [11]—can significantly affect image quality for certain
modalities, however the detrimental effect of implants on MR imaging is changing with
increased usage of non-metallic implants [12].
6Figure 1.1: An untreated 78-year-old man with serum PSA of 9.8 ng/mL showing a, A
coil-corrected T2-weighted FSE image, BMRSI choline metabolite map created in SIVIC [6],
C rFOV ADC map (b = 0, 600 s/mm2), D coil-corrected rFOV DWI (b = 0, 1350 s/mm2),
and DCE-derived semi-quantitative parameters of E enhancement slope, and F washout
slope. Subsequent TRUS–MRI fusion-guided biopsy revealed a Gleason 4+3 lesion in the
left apex, indicated by white arrows.
7The mpMRI of the prostate, however, suffers from lack of standardization, leading to
variable performance between sites. The American College of Radiology (ACR), the Euro-
pean Society of Urogenital Radiology, and the AdMeTech Foundation have proposed the use
of the Prostate Imaging Reporting and Data System (PI-RADS), now in its second version
[13]. In PI-RADS, the ACR describes the minimum recommended parameters for imag-
ing patients, among other important aspects of mpMRI. In this chapter, we discuss various
aspects of imaging acquisition and suggest protocols that may be used for more optimal
assessment of patients with prostate cancer.
MpMRI prostate imaging was initially implemented on 1.5-Tesla (1.5T) scanners [14] [15].
To acquire scans with diagnostic value, a pelvic phased array was used in combination with
and an endorectal coil (ERC) [16]. In prostate MR imaging, ERCs can provide a nine-fold
improvement in the signal-to-noise ratio (SNR) and spatial resolution when compared to
pelvic phased array coils alone [17]. This has a profound impact on the quality of functional
imaging, such as MRSI and DWI. Traditional ERCs use a balloon-filled coil, inflated with
40–80 mL of either an inert fluid that matches the susceptibility of the prostatic tissues, such
as perfluorocarbon (PFC) [17], or with air or water. Using an inert fluid instead of air or
water improves the homogeneity of the magnetic field and decreases susceptibility artifacts
between the rectum and the prostate [18]. Using either a rigid or an inflatable ERC will
create an inhomogeneous reception profile which results in higher signal intensity near the
rectal wall and may hinder cancer detection in the peripheral zone. Fortunately, this signal
non-uniformity can be easily rectified using readily available coil-correction software [19].
8The introduction of 3-Tesla (3T) clinical scanners presented an opportunity to enhance
image quality by trading the increased SNR for improvements in spatial and temporal res-
olutions, decreasing the necessity of an ERC. The nine-fold SNR increase provided by an
ERC can only be partially replaced by a two-fold SNR improvement in doubling the magnet
strength. Nevertheless, with advances in pulse sequence design, several groups reported that
studies done solely with 6 to 32 phased array surface coils at 3T yielded comparable images
as the exams conducted with 1.5T scanners with an endorectal coil [20]. A comparison study
with and without an ERC at 3T showed increased sensitivity (0.45, no ERC and 0.75, with
ERC) and positive predictive value (0.64, no ERC and 0.80, ERC) for prostate cancer de-
tection [21] when using an ERC (Fig. 1.2). However, considering patient discomfort, patient
preparation, costs, coil placement time, and anatomical distortion associated with ERCs,
the use of ERCs in prostate imaging is still being actively debated. An important note on
this point is the different aims of prostate cancer imaging. In the U.S., an mpMRI of the
prostate is generally performed to assist in treatment planning, after either positive biopsy
or serial negative biopsies with abnormal blood work or family history. Elsewhere, as in the
E.U., much abbreviated mpMRIs of the prostate are performed as a diagnostic procedure
without necessary clinical presentation other than advanced age [22]. In that setting, it is
easy to see why invasive hardware for marginal quality gain is of less importance than hos-
pital throughput. In this work, we focus on the mpMRI of the prostate as performed in the
U.S., with the priority of creating images with the sensitivity to discern disease extent and
aggressiveness to assist clinicians in treatment planning.
9Figure 1.2: An untreated 66-year-old man with no prior biopsies and serum PSA of 7.9
ng/mL. Oblique axial 2D FSE T2-weighted images acquired with 0.35 x 0.35 x 3 mm, A
with an endorectal coil and B without an endorectal coil. This patient was scanned twice in
3 months in anticipation of the MR-guided biopsy. We observe a noticeably increased noise
in the image without an ERC, as well as diminished delineation between nodules inside the
gland.
We have anecdotally noted that providing patients with information detailing the proce-
dure and the required preparation prior to the exam can improve patient compliance. Pa-
tients with severe claustrophobia may be required or advised to bring prescription sedatives
to the exam. In some centers, antispasmodic agents like butylscopolamine are administered
immediately prior to scanning to decrease bowel peristalsis and potential artifacts related
to motion. However, peristaltic suppression is controversial, and some groups have failed to
identify a significant improvement of image quality in studies performed on 3T scanner with-
out an ERC [23]. Patients undergoing scans with an ERC should be advised to perform a
saline laxative enema within a three-hour window of the exam to facilitate proper endorectal
coil placement and minimize susceptibility artifacts associated with air or fecal contamina-
tion. Enemas are not required prior to scans done without an ERC, as the improvement in
image quality is at best marginal [24].
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1.2 Anatomic T1- and T2-weighted Imaging
The foundation of the mpMRI, and MR imaging, is high-resolution T1- and T2-weighted
acquisitions. So-called “anatomic imaging” for the ability to delineate anatomy by combining
high resolution with soft tissue contrast, these acquisitions are based on the two principle
relaxation phenomena of nuclei returning to equilibrium after excitation by a radiofrequency
pulse [25].
To create an MR signal, equilibrium is established by a main magnetic field B0 and
perturbed by a radiofrequency pulse B1. Relaxation, the return to thermal equilibrium, is
the time when MR signals are recorded. It is the difference in the relaxation time constants
of nuclei in different microenvironments that gives rise to the most basic of MR images. The
process is described fundamentally by the Bloch equation:
dM
dt
=M× γB− Mxi+Myj
T2
− (Mz −M0)k
T1
(1.1)
with precession of the net magnetization M around a magnetic field B, typically described
as vectorsM=(Mxi, Myj, Mzk) and B=(Bxi, Byj, Bzk), in a 3D coordinate system. Calling
the main magnetic field in the z-direction B=B0k, the magnetization vector M before RF
excitation points along the vector B:
M =M0k (1.2)
We denote M0 as the net equilibrium magnetization, a physical property of the magnetized
sample dependent on the concentration of nuclear spins, temperature, strength of the mag-
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netic field, and Boltzmann’s constant. An RF pulse at the resonant frequency of the sample
and perpendicular to the z-direction can induce torque on the magnetization vectorM, which
will precess around the main magnetic field B0 until returning to thermal equilibrium. The
relaxation in the direction of the main magnetic field, ignoring the effects of precession, is
shown in Eqn 1.3 by the behavior:
dMz
dt
=
(Mz −M0)k
T1
(1.3)
which has a general solution of:
Mz(t) =M0 + (Mz(0)−M0) exp(−t/T1) (1.4)
The system will dissipate power over a period of milliseconds as the magnetization returns
to thermal equilibrium where M = M0k. This is the longitudinal relaxation, or T1 decay, of
the sample in the system. Magnetization along the longitudinal axis according to T1 decay
is shown in Figure 1.3.
A multiparametric MR imaging exam of the prostate typically includes a large field-of-
view, axial T1-weighted scan of the pelvis to assess regional lymph nodes for abnormal size,
shape, or intensity. Identification of these lymph nodes is facilitated by the T1 contrast be-
tween the high signal intensity of visceral fat and lower signal intensity of large or irregularly
shaped lymph nodes [26]. To ensure that the lymph nodes in the drainage pathway are
imaged during the exam, the T1-weighted scan prescription should extend superiorly to the
aortic bifurcation [27]. In addition, these T1-weighted images offer an opportunity to de-
12
Figure 1.3: T1 Decay over 60 Seconds according to Eqn 1.4.
tect osseous metastases. While lesions will be incompletely assessed with a single sequence,
after correlation with clinical history and histology, further diagnostic steps may be taken.
T1-weighted imaging is also useful to diagnose post-biopsy hemorrhage, which demonstrates
high signal intensity [26]. Hemorrhage often has low T2 signal intensity, mimicking cancer,
and may introduce significant artifact on DWI and 1H-MRSI, and confound results from
DCE MR imaging. For this reason, an interval of at least 6 weeks between the most recent
prostate biopsy and the MRI scan is recommended [28].
T2 decay, relaxation of the net magnetization vector M along the plane transverse to the
main magnetic field B0, is a loss of phase coherence in Mxy [25]. Before excitation, when M
= M0k, there is phase coherence along the longitudinal axis. The detectable signal in Mxy
immediately begins to decay after the RF pulse. The relaxation is described as:
13
dMxy
dt
=
Mxi+Myj
T2
(1.5)
which has a general solution of:
Mxy(t) =M0 exp
(−t/T2) (1.6)
Because the loss of coherence decreases the net magnetization vectorM inMxy, the resulting
T2 decay curve decreases with return to thermal equilibrium. Furthermore, because a system
in a large magnetic field will undergo simultaneous T1 decay, and there is phase coherence
when M = M0k, T2 ≤ T1. Magnetization along the longitudinal axis according to T2 decay
is shown in Figure 1.4.
Multiplanar high-resolution two-dimensional (2D) fast spin-echo (FSE) T2-weighted MR
images provide exquisite soft-tissue contrast and excellent depiction of zonal anatomy, and
are the backbone of MR imaging of the prostate. The majority of prostate cancers are ade-
nocarcinomas that arise within the peripheral zone, which have low signal intensity against
the background of the bright peripheral zone tissue on T2-weighted imaging. Transitional
zone tumors represent most of the remaining prostate cancers. Similarly to peripheral zone
cancers, these lesions usually have low signal intensity on T2-weighted imaging but can be
difficult to distinguish from benign tissue, in particular in the presence of benign prostatic
hyperplasia (BPH). T2-weighted imaging is also the main sequence utilized to assess local
spread of cancer, however the diagnostic accuracy is higher when it is combined with other
functional sequences [29].
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Figure 1.4: T2 Decay over 60 Seconds according to Eqn 1.6.
High-resolution 2D FSE T2-weighted images are acquired in the true sagittal plane, as
well as the oblique axial (Figure 1.1) and oblique coronal planes of the prostate. The slice
thickness should not be more than 3 mm, without a gap, and the in-plane dimension of
≤ 0.7mm (phase) x ≤ 0.4mm (frequency). For most patients, a field-of-view of 12–18 cm
will include the entire gland and seminal vesicles. High-resolution 3D FSE T2-weighted MR
imaging has emerged as a promising technique that allows for the acquisition of isotropic
images and may save time by reducing the number of sequences that need to be obtained.
However, the quality of the 3D sequence may be limited if acquired on older or low-field
magnets due to the need for thinly sliced images for adequate reformatting. While the T2
contrast is not the same as seen in 2D acquisitions, it is clinically acceptable [30]. Data of
a study by Westphalen et al. showed that the preference for the 2D or 3D FSE MR images
varies widely among radiologists, but without differences in their ability to delineate the
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Figure 1.5: An untreated 61-year-old man with biopsied Gleason 3 + 3 prostate cancer
and serum PSA of 5.6 ng/mL showing an oblique axial, A T2-weighted FSE anatomic image
and B T2-weighted 3D FSE anatomic image. The phase-encoding direction aliasing artifact
present in the FSE image is not present in the CUBE image. However, the 3D FSE image
has less contrast in comparison to the 2D FSE
anatomy and identify cancer [31]. This same study did find differences in image sharpness
and the presence of some artifacts. The 2D FSE images were sharper than the 3D ones but
demonstrated more artifacts (Figure 1.5).
1.3 Diffusion-weighted Imaging
Diffusion-weighted imaging (DWI) exploits the random motion of water molecules in biolog-
ical tissues to characterize disease. Water molecules travel through nearly all tissues and,
as in T1- and T2-weighted imaging, our resulting image is a record of differences in the rate
of the phenomenon over a unit of time. DWI is typically performed using a pulsed gradient
spin-echo approach originally presented by Stejskal and Tanner [32], shown in Figure 1.6.
After excitation into the transverse plane, equal amplitude and duration gradients (called
diffusion gradients) are played on either side of a 180◦ refocusing pulse. After the first
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Figure 1.6: Stejskal-Tanner pulsed gradient diffusion model [32].
diffusion gradient, molecules will accumulate phase. After the refocusing pulse, a molecule
experiencing no change in position will see the same gradient power in opposing directions,
cancelling any accumulated phase and restoring the signal amplitude to its strength before
the diffusion gradients. A moving molecule, however, will experience two different diffusion
gradients based on two positions in time. This mismatch leads to phase accumulation and
weaker signal strength.
The amount of motion the pulsed gradient spin-echo approach can detect is determined
by the diffusion gradients [25]. The magnitude (G), duration (δ), and interval (Δ) of the
gradient lobes in Figure 1.6 can be tuned based on the limits of given hardware. The b-value
in DWI is a conglomerate variable reflecting the gradient shape and timing:
b = γ2G2δ2(∆− δ
3
) (1.7)
which can be simply related to the signal strength after the diffusion gradients have been
played:
S = S0(e
−bD) (1.8)
The b value measures movement in units of s/mm2. Generally, a shorter b-value will create
a signal dominated by particles moving long distances, and is useful for the study of vas-
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culature. A longer b-value will capture signal from particles traveling over small distances,
and can show differences in tissue microstructure and cell density.
Interpreting the difference in signal in the context of current prostate MRI requires two
more steps. First, because diffusion gradients are directional, images are obtained in—usually
three or six—different directions and combined to form a trace image:
SDWI = S0(e
−b (Dx+Dy+Dz)
3 ) (1.9)
The trace consolidates the directional diffusion of molecules in a tissue into a single number.
However, because diffusion measures dephasing, the resulting signal can reflect the inherent
T2-weighting of the spin-echo sequence, a phenomenon known as T2-shine-through [25]. To
remove the effect of this simultaneous T2 decay, the trace image is divided by a reference im-
age with similar echo timing and a b-value of 0 s/mm2, with the natural logarithm correcting
for exponential decay. The resulting apparent diffusion coefficient (ADC) is a directionless
metric of diffusion without the effects of T2-weighting:
ADC = −1
b
ln(
SDWI
S0
) (1.10)
The glandular structure of the normal peripheral zone of the prostate compared to the
shrunken glands or tightly packed cancerous tissue defines a well-established contrast be-
tween healthy and tumor tissue on DWI and the corresponding ADC maps [33]. Perhaps
not surprisingly, DWI has been shown to increase the sensitivity and specificity of multi-
parametric MR imaging for the detection of prostate cancer [22]. Some studies have shown
improvement in the assessment of tumor aggressiveness when combined with conventional
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T2-weighted imaging, with an inverse relationship between the ADC map intensity and the
Gleason score [34]. A threshold of approximately 850 x 106 mm2/s has been used to distin-
guish between low- and high-grade tumors [35]. However, substantial overlap of ADC values
is commonly seen between cancer and confounders like inflammation and benign prostatic
hyperplasia (BPH), and variability across the various imaging platforms due to different ac-
quisition parameters prevent DWI metrics from being recommended bases for aggressiveness
and have not been accepted into the PI-RADS v2 standard [13].
For prostate cancer detection on 3T scanners, the b-values are generally divided into mid
(between 500 and 800 s/mm2) and high (between 1000 and 2500 s/mm2) (Figure 1.1) [36],
where using a lower b-value emphasizes extracellular effects in the resulting ADC maps, and
using a high b-value emphasizes intracellular motion. Limits in gradient hardware on older
magnets may exclude b-values above 1000 s/mm2. Recently, it has become popular to utilize
more than one b-value for the assessment of prostate cancer. Imaging with a mid-range b-
value will normally have a greater SNR, which can result in finer resolution and a decreased
number of signal averages per image. However, a high b-value acquisition reduces the signal
from normal prostatic tissue and vasculature, increasing the sensitivity to abnormal cellular
environments [37]. One method of gaining the advantage of contrast of a high b-value while
still having the high SNR and fine resolution of a lower b-value acquisition is to extrapolate
and compute the theoretical image output for higher b-values. These images show higher
SNR than traditional DWI collected with the equivalent high b-values and can be utilized on
older 1.5T scanners where gradient hardware may not allow acquisition with high b-values
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[38].
In addition to more heavily diffusion-weighted images, a low b-value image is acquired
with a b-value in the range of 0–100 s/mm2. This image serves as a reference, to fit a slope
to the signal per b-value per direction, which is combined to define the ADC map. The lower
b-values are also used because they remove the effect of perfusion on the resulting ADC map.
In order to easily associate structural T2-weighted images with functional DWI data, DWI
should be performed with the same or similar slice thickness and acquisition prescription to
high-resolution T2-weighed imaging. DWI can be performed immediately after T2-weighted
imaging to increase structural similarity.
DWI is heavily affected by susceptibility artifacts, which increase in magnitude with
higher field strength [39]. Images acquired with EPI, in particular, suffer from severe sus-
ceptibility artifact at the interfaces of tissue with air, blood, or fecal matter in the rectum.
These artifacts are important because they present at the border of the rectum and affect
the peripheral zone of the prostate, where 70% of cancers are located [40]. Performing a
rectal enema before the exam reduces susceptibility artifact from air or fecal matter in the
rectum [41]. A promising recent development for artifact reduction is reduced Field-of-View
imaging, which has been shown to improve image quality and contrast between tumor and
healthy tissue, as well as to decrease susceptibility artifact in prostate DWI [42] (Fig. 1.7).
This technique will be discussed in detail in Chapter 2.
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Figure 1.7: An untreated 74-year-old man with biopsied Gleason 3+3 prostate cancer and
serum PSA of 6.85 ng/mL. An oblique axial A T2-weighted 2D FSE anatomic image, B
rFOV ADC map, and C full FOV ADC map show the advantages of the rFOV method for
distinguishing boundaries of the prostate and BPH nodules within the prostate. We also see
susceptibility artifact from fecal matter or air in the rectum, which significantly blurs the
rectal wall on C and less so on B.
1.4 Dynamic Contrast-enhanced Imaging
Dynamic contrast-enhanced imaging follows the time course of tissue enhancement before,
during, and after injection of a contrast agent to evaluate the properties of tissue microstruc-
ture and neovascularity. The most common MR contrast agents are chelated forms of a
gadolinium ion [43]. Gadolinium has several important properties that make it an ideal
magnetic contrast agent, most importantly that it is biologically inert and paramagnetic,
and it maintains these properties when chelated.
The gadolinium ion’s signal isn’t acquired directly; rather it’s the effect of gadolinium’s
magnetic moment on the surrounding hydrogen atoms that we measure [25]. The net mag-
netic moment of gadolinium in a tissue is proportional to the number of chelated gadolinium
ions that have permeated the tissue. This net magnetic moment aligns with the main mag-
netic field B0k, strengthening the local B0 field and shortening the T1 relaxation time of
surrounding hydrogen ions. Dynamic T1-weighted images reflect a difference in signal inten-
21
sity in regions of similar tissues with different amounts of injected gadolinium. Gadolinium
is therefore used as a perfusion agent, and is popular in cancer diagnostics to measure tumor
angiogenesis.
Prostate cancer, specifically, brings about numerous changes in the cellular structure
of the tissues, resulting in tissue alterations that can be measured with injected contrast.
It is believed that MR contrast agents do not reach the lumen of the healthy glandular
tissues [44]. Conversely, prostate cancer is marked by the loss of the basement membrane
outside the glandular epithelial cells, which allows the contrast to enter the glands, resulting
in a greater and faster tissue enhancement. In addition to continuing alterations in tissue
microstructure, prostate cancer progression is also associated with neoangiogenesis [45]. The
rapid growth and division of tumor vasculature result in disorganized, irregularly shaped,
immature vessels [46]. DCE takes advantage of the unique characteristics associated with
the abnormal tumor vasculature to assess aggressiveness of the disease. The usefulness of
DCE in detecting, localizing, and staging prostate cancer is well documented in literature
[47]. Additionally, several studies have reported promising findings on the utility of DCE
parameters in discriminating prostate cancer based on aggressiveness of the disease [48].
However, these results are often confounded by the presence of prostatitis in the peripheral
zone or by mixed BPH nodules in the central gland [1] [4].
DCE imaging is often done with a 3D Fast Spoiled Gradient Echo (3D-FSPGR) pulse
sequence. T1-weighted images are collected before, during, and after administration of a
contrast agent. A DCE scan is often preceded by a T1 mapping, a measurement of the native
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tissue relaxation time ( T1,0) obtained using a series of volume acquisitions with variable flip
angle values. Once the native T1 mapping is complete, several pre-contrast dynamic T1-
weighted volumes are acquired to establish a baseline. The contrast agent is administered
as an intravenous bolus at a rate of 2-4 ml/s followed by a 20-mL saline flush using a power
injector. To ensure patient safety, patient’s kidney function should be evaluated prior to
contrast injection. Estimated glomerular filtration rate (eGFR) based on the blood creatinine
levels are often used as indicators of kidney health. Once injected, the contrast agent does
not penetrate the healthy prostate glands but collects in the extravascular extracellular space
(EES), where it serves to shorten local relaxation times, producing high signal intensity on
T1-weighted images.
DCE-MRI studies typically utilize weight-adjusted (0.1 mmol/kg of body weight) para-
magnetic gadolinium chelate contrast agents. There are several agents approved by the
United States Food and Drug Administration, including gadopentetate dimeglumine (Mag-
nevist), gadobutrol (Gadovist), or gadodiamide (Omniscan) [43]. Aiming for a reasonable
spatiotemporal resolution, a five-minute DCE acquisition yields dynamic imaging with a
temporal resolution in the range of 3-10 s, a spatial resolution in the range of 0.7x0.7 mm
to 1.9x1.9 mm with a slice thickness of 3-4 mm [30]. Compressed sensing techniques can
improve spatiotemporal resolution or increase the coverage in DCE acquisitions. Recently,
Rosenkrantz et al. reported the use of a high-spatiotemporal resolution DCE technique
GRASP (Golden-angle Radial Sparse Parallel) imaging, which allows for image acquisition
with spatial resolution of 1.1x1.1x3.0 mm and temporal resolution of 2.3 s [49].
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Tissue enhancement observed during DCE can be interpreted either by visually inspecting
the raw images (qualitative approach) or by using semi-quantitative or quantitative methods
[50]. The qualitative analysis of the DCE images [51] is based on the premise that the blood
vessels recruited by the prostate tumors are leaky [52]. When the contrast is injected, the
cancerous tissues demonstrate early and rapid enhancement followed by a quick washout,
which is noticeably different from a slow and steady enhancement observed for normal tissues.
An observer may evaluate regions of interest within the prostate by categorizing the overall
enhancement as 1) persistent—a steady enhancement, usually indicative of benign pathology,
2) plateau—the initial uptake is followed by a constant enhancement, slightly suspicious
for malignancy, and 3) washout—a sharp uptake is followed by a steep washout, strongly
suspicion for malignancy (Figure 1.8).
While the qualitative approach is quick and intuitive, it fails to comprehensively assess
heterogeneous tissues and is inherently subjective and difficult to standardize among imaging
centers. Semi-quantitative analysis characterizes the enhancement curve on a voxel by voxel
basis by calculating curve parameters such as maximum enhancement slope (Figure 1.1),
time to peak, peak enhancement, washout slope, and area under the curve [48]. Although
this approach is extensively used in the assessment of DCE-MRI, the semi-quantitative
parameters provide little physiologic insight into behavior of the tumor vessels and the
usefulness of the computed metrics can be limited when comparing data across different
imaging protocols. Normalization to muscle has been suggested to aid in generalization of
semi-quantitative parameters [44].
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Figure 1.8: Three main types of overall enhancement seen in prostate tissues: persistent
enhancement, typically indicative of benign pathology (green); plateau, slightly suspicious
for malignancy (blue); and washout, strongly suspicious for malignancy (red).
The final approach to analyzing DCE images aims to estimate physiologically inter-
pretable, kinetic parameters by fitting pharmacokinetic models to the enhancement curves
[53] [54]. The most common is the two-compartment model, where the two compartments
are the plasma space of the vasculature and the interstitial space between the prostate cells.
The two main parameters derived from such models are Ktrans (the volume transfer constant
between plasma and extracellular space, expressed in units of min−1) and ve (the fractional
volume of extracellular space per unit volume of tissue) [55]. While Ktrans maps offer di-
agnostically valuable information, acquiring stable measurements from quantitative analysis
remains a challenge. Quantitative methods are affected by a number of variables such as
changes in cardiac output, accurate tissue T1 and arterial input function (AIF) measure-
ments, as well as the underlying assumptions made by the software packages. Accuracy of
T1 measurements is greatly aided by T1 mapping [56]. Ideally, the AIF (the concentration
of the contrast agent in the feeding blood supply) is measured for each individual patient
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in the femoral artery [57]. Unfortunately, in a clinical setting, the required temporal reso-
lution may be difficult to achieve. Finally, there are several open-source and commercially
available software packages for both clinical and preclinical quantitative DCE analyses [58]
[59] [60]. However, few studies have been done to assess reproducibility of pharmacokinetic
measurements obtained with different software packages.
The second version of PI-RADS highlights the fact that DCE-MRI can be and is most
widely assessed based on direct visualization of the raw data; optional tools, e.g., parametric
maps and compartmental models, can be used to assist in diagnosis, but findings should
always be confirmed on source images [13]. PI-RADS v2 characterizes a positive finding on
DCE-MRI as a lesion with focal enhancement, earlier or contemporaneous with enhancement
of adjacent normal tissues, and that corresponds to a suspicious finding on T2- or diffusion-
weighted MR images.
1.5 1H MR Spectroscopic Imaging
Benign and malignant tissues can also be differentiated based on the metabolic changes
associated with prostate cancer [61], and proton magnetic resonance spectroscopic imag-
ing (1H-MRSI) has been established as a powerful technique for assessing in vivo cellular
metabolism. MRSI combines the spatial localization of imaging with traditional nuclear
magnetic resonance (NMR) to discern relative metabolite abundance within tissues. The re-
sult can be viewed as a matrix of NMR spectra, or as maps of relative metabolite abundance
as in the choline map in Figure 1.1.
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The ability of NMR to distinguish metabolites in a tissue is based on the small differences
in magnetic microenvironment experienced by protons in different molecular configurations.
The electron cloud surrounding each proton creates a small shield from the main magnetic
field B0, and the small changes in the ‘effective’ B field of each proton results in small
differences in resonant frequency, a phenomenon known as chemical shift. The chemical
shift of each proton is measured by its difference in frequency from a reference molecule,
usually the stable and well-shielded trimethylsilane (TMS), as describe by Eqn 1.11.
δ =
fsample − freference
freference
(1.11)
The chemical shift is a dimensionless constant dependent on nucleus and molecular con-
figuration, typically measured in parts per million (PPM), which simplifies language when
accounting for the six orders of magnitude between precession (MHz) and chemical shifts
(Hz). PPM is also independent of field strength.
Normal prostatic glandular epithelial cells produce and secrete high levels of citrate
(2.5–2.7 ppm) (Fig 1.9) [62]. Prostate cancer disrupts the epithelial tissues and triggers
a metabolic shift from citrate production to citrate oxidation; the overall effect is a substan-
tial reduction in citrate levels in malignant prostate tissues [63]. Furthermore, increased cell
density and elevated cell membrane turnover lead to increased levels of choline (3.21 ppm) in
prostate cancer [64]. Creatine (3.02 ppm) is another metabolite of interest; it is maintained
at a relatively constant level in both healthy and malignant prostatic tissues and serves as an
internal reference. Lastly, some groups found it informative to track metabolic changes asso-
ciated with polyamine [61]. Polyamines (especially spermine) are found in healthy prostate
27
Figure 1.9: An untreated 78-year-old man with serum PSA of 9.8 ng/mL. MRSI demon-
strating highly elevated choline (right panel) in the left apex, drastically different from the
contralateral healthy tissues (left panel) that demonstrate high citrate signal without ele-
vated choline. Subsequent TRUS–MRI fusion-guided biopsy revealed a Gleason 4+3 lesion
in the left apex.
epithelial cells, and similar to citrate, their levels are dramatically reduced in prostate cancer
[65].
Due to the multifocal nature of prostate cancer, a high-resolution metabolic mapping
of the entire prostate is required for accurate cancer localization and diagnosis. The 1H-
MRSI acquisition has evolved from single-voxel spectroscopy to 3D 1H-MRSI that is typically
acquired using phase encoding in all three directions, but is time consuming. Improvements
in pulse sequence design have enabled the acquisition of metabolic information from the entire
prostate at high resolution within less than 10 min with voxel sizes ranging from 0.2 to 0.5
cm3, making 1H-MRSI a clinically feasible technique [66]. These include using flyback echo-
planar readout gradients to improve efficiency and robustness to errors and non-uniform
undersampling, and compressed sensing to accelerate the acquisition [67]. A number of
techniques have been used to reduce the negative effects of periprostatic fat, including outer
volume saturation (OVS) with very selective suppression (VSS) pulses [68], band-selective
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inversion with gradient dephasing (BASING) [69], and spectral-spatial radiofrequency pulses
[70].
The 1H-MRSI sequence is usually prescribed off the axial T2-weighted MR images with
a volume selected to maximally cover the prostate while excluding the seminal vesicles,
periprostatic fat, and as much of the rectum as possible. Standard post-processing involves
zero-filling, apodization using Gaussian or Lorentzian filtering, and Fourier transform of the
free induction decay signal, as well as baseline and phase corrections [6].
Interpretation of 1H-MRSI data is often done on a voxel-by-voxel basis, which can be
time consuming and introduce interobserver variability. An alternative approach to review
these metabolites is to observe peak area ratios, such as the choline + creatine to citrate
ratio within each voxel; choline and creatine are typically combined due to signal overlap.
In 2004, Jung et al. proposed a standardized scoring system for peripheral zone tissues
based on metabolic data, ranging from 1 (definitely normal) to 5 (definitely cancer) [71].
And in 2007, Futterer et al. introduced standardized thresholds for differentiation of benign
and malignant tissues in the peripheral zone and central gland of the prostate [72]. Several
studies reported significant correlations between peak area ratios and Gleason scores [73]
[74]; yet, interpretation can be hindered by choline contamination from the seminal vesicles
or urethra [75] or by prostatitis [76], which can result in false positive findings.
It is also important to note that the data of some studies were unfavorable to the clini-
cal usefulness of 1H-MRSI, more notoriously those of the ACRIN 6659 study published by
Weinreb et al. that found no incremental benefit for 1H-MRSI compared with MRI alone
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in sextant tumor localization [15]. Based on such data, and possibly on the complexity of
imaging acquisition and interpretation, 1H-MRSI, which was an optional tool in the initial
version of PI-RADS, no longer influences the assessment of lesions in PI-RADS v2 [13].
1.6 13C MR Spectroscopic Imaging
Imaging with an injectable, radioactively labeled accumulating agent as is done in 18F -
fluorodeoxyglucose Positron Emission Tomography (PET) imaging can eliminate the back-
ground signal that often hampers the specificity of 1H-MRSI. There is considerable interest in
the development of injectable, non-radioactive, MR-based agents that could probe metabolic
changes in tissue without the background signal inherent to proton imaging, specifically
agents whose natural abundance is less ubiquitous in the body.
While many probes have been developed in recent years, labeling with carbon-13 (13C),
i.e. replacing 12C (98.9% natural abundance) with MR-sensitive 13C (1.1% natural abun-
dance), has the potential to detect and track the metabolism of a large number of organic
metabolic substrates, like glucose and glutamine. In cancer imaging, 13C-labeled pyruvate
can provide a measure of the Warburg effect: that after glycolysis cancerous cells tend to
favor lactic acid fermentation by lactate dehydrogenase (LDH) over the more common and
energy-efficient oxidative phosphorylation [77]. Preference for either metabolic pathway can
therefore be studied by injecting 13C labeled pyruvate, the end product of glycolysis, and
observing the amount of resulting 13C labeled lactic acid.
There are several practical hurdles to 13C imaging: frequency-specific hardware, and low
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sensitivity. 13C has a gyromagnetic ratio of 6.7x107 rad/T/s [78], almost exactly 1/4 that of
1H, so dedicated transmit and receive hardware tuned to the resonant frequency of 13C must
be available to perform carbon imaging. Because high-resolution anatomic proton imaging is
often desired along with functional carbon, dual-tuned RF coils are common. Multinuclear
RF coil design is discussed in detail in Chapter 4. Pulse sequences must also be adjusted,
specifically to account for the differences in power absorption and relaxation times.
The low natural abundance of 13C has the major benefit of reducing background signal;
however the low sensitivity creates low signal of an injected probe as well. 13C imaging over
many hours to compensate for this low sensitivity is common in ex vivo experiments, but
impractical for the clinic, where sufficient signal needs to be generated before the probe is
cleared from the system. A practical solution is to overcome the natural, thermal polarization
level of the sample determined by the Boltzmann distribution:
N+
N−
= exp
−∆E
kT (1.12)
Where N+/N- is the ratio of parallel to anti-parallel alignments, ΔE is the difference in
energy level, K is the Boltzmann constant and T is temperature. Close to absolute zero, spins
overwhelmingly prefer parallel alignment to the main magnetic field. However as increasing
temperature increases the energy in the environment, the conglomerate effects of random
motion tend to equilibrate preference in alignment, and decrease the net magnetization
vector. Creating nonthermal polarization levels in liquid solutions at body temperature is
done using a process called dynamic nuclear polarization (DNP), which can increase the
resulting signal-to-noise ratio of an injectable probe by over 10,000-fold [79].
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Figure 1.10: A Representative calculated pyruvate-to-lactate flux (kPL) images overlaid
on corresponding T2-FSE reference images from a low-grade (left) and a high-grade (right)
TRAMP tumor. At pathology, a region of necrosis was observed in the anterior aspect of
the tumor (red arrow). B Box plots showing individual (diamonds), median, and standard
deviation kPL flux measurements in the 9 low-grade and 10 high-grade TRAMP tumors. C
LDH activities for the same TRAMP tumors. D A bar plot showing the fraction of cells
staining positive for Ki-67 (mean ± SE) ⋆ significantly different; p<0.001.
This hyperpolarized 13C probe can be imaged in vivo to track the metabolic conversions
of the injected substrate in real time, a diagnostic feature without equal in traditional MR
or radiologic imaging [80]. In murine models, the measurement of the Warburg effect using
hyperpolarized [1-13C]pyruvate correlates with traditional histpathological staging of disease
aggressiveness (Figure 1.10) [81] [82]. Chapter 5 explores current advances in [1-13C]pyruvate
in human prostate cancer in detail.
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1.7 Conclusion
Use of mpMRI exams for the staging and improved characterization of prostate cancer has
become prominent at medical centers around the world [22] [83] [84] and is likely to continue
expanding into increasing modalities in the age of precision medicine. However, the mpMRI
of the prostate has not gained the same level of acceptance of other imaging tests, at least in
part due to the lack of standardization and inadequate patient preparation. Discrepancies
in pulse sequence design can create exams vulnerable to artifact, and sequence design is
limited by currently available hardware. Even in state-of-the-art imaging, differentiating
between similar appearing tissues is challenging. Benign conditions like chronic inflammation
can masquerade as low-grade cancer, and cancer aggressiveness cannot be measured by the
current mpMRI. In this work, we provide solutions to the above concerns through innovations
in pulse sequence design and hardware, novel analytic methods, and clinical application of
hyperpolarized 13C-MRSI.
Finally, regardless of the magnet strength, the use of an endorectal coil, or the details
of the imaging protocol, patient preparation is essential to acquiring the highest quality
images while maintaining maximal patient comfort and compliance. Equally important in
providing the best imaging exam for patient diagnosis is the communication between primary
physicians, radiologists, researchers, and staff.
33
Chapter 2
A Reduced-FOV Excitation Decreases
Susceptibility Artifact in Diffusion-
weighted MRI for Prostate Cancer
Detection
Abstract
The purpose of this study was to determine if image distortion is less in prostate MR apparent
diffusion coefficient (ADC) maps generated from a reduced-field-of-view (rFOV) diffusion-
weighted-imaging (DWI) technique than from a conventional DWI sequence (FULL), and
to determine if the rFOV ADC tumor contrast is as high as or better than that of the
FULL sequence. Fifty patients underwent a 3T MRI exam. FULL and rFOV (utilizing
a 2D, echo-planar, rectangularly-selective RF pulse) sequences were acquired using b=600
and 0 s/mm2. Distortion was visually scored 0–4 by three independent observers and quan-
titatively measured using the difference in rectal wall curvature between the ADC maps
and T2-weighted images. Distortion scores were lower with the rFOV sequence (p=0.012,
Wilcoxon signed-rank test, n=50), and difference in distortion scores did not differ signifi-
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cantly among observers (p=0.99, Kruskal-Wallis test). The difference in rectal curvature was
less with rFOV ADC maps (26±10%) than FULL ADC maps (34±13%) (p=0.011, student’s
t-test). In seventeen patients with untreated, biopsy confirmed prostate cancer, the rFOV
sequence afforded significantly higher ADC tumor contrast (44.0%) than the FULL sequence
(35.9%), (p=0.0012, student’s t-test). The rFOV sequence yielded significantly decreased
susceptibility artifact and significantly higher contrast between tumor and healthy tissue.
2.1 Introduction
Diffusion-weighted imaging (DWI) increases both sensitivity and specificity in prostate can-
cer detection in multiparametric MR studies [21]. DWI has also been shown to improve the
assessment of tumor aggressiveness when combined with conventional T2-weighted imaging,
with an inverse relationship between the apparent diffusion coefficient (ADC) map inten-
sity and Gleason score [34]. DWI typically uses the echo-planar imaging (EPI) technique
to decrease scan time. However, images acquired with EPI suffer from severe susceptibility
artifact at the interfaces of tissue with air, blood, or fecal matter in the rectum. These
artifacts are of particular importance because they present at the border of the rectum and
the peripheral zone of the prostate, where 70% of prostate cancers are located [40].
In this work, we have utilized a reduced-field-of-view (rFOV) acquisition scheme for
prostate DWI that employs a 90◦ 2D spatially-selective, echo-planar RF pulse to excite
a limited extent of the Field-of-View (FOV) in the phase encoding direction [85]. This
enables a higher spatial resolution to be achieved in the phase encoding direction than in
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conventional DWI with a shorter echo-train length, and without obvious aliasing artifacts.
The reduced echo-train length can potentially reduce prostate image distortions induced by
magnetic-susceptibility differences within the FOV [85]. Additionally, this pulse is designed
so that the excited fat profile and the excited water profile are displaced in volume in the slice-
selective direction, and only the on-resonance water profile can be selected by the subsequent
refocusing pulse. This displacement in volume (Δdcs) is dependent on the chemical shift
between fat and water (fcs), as well as the number of blips (Nblips), the extent of k -space
traversed per blip (kblip), and the duration of the gradient lobe (Tfast). This could potentially
provide a robust method of periprostatic fat suppression in prostate DWI images.
The aim of this study was to determine if image distortion is less in prostate ADC maps
generated from the rFOV technique than from a conventional DWI sequence (FULL) and to
determine if the rFOV ADC contrast between tumors and healthy-appearing tissue within
subjects is as high as or better than that of the FULL sequence.
2.2 Materials and Methods
This prospective study was approved by our institutional review board and was compliant
with the Health Insurance Portability and Accountability Act. Written, informed consent
was obtained from all participants. Fifty patients receiving MR examinations of the prostate
were studied between September of 2011 and January of 2013. Patients presented with
suspected prostate cancer, as indicated by either elevated levels of serum prostate-specific
antigen (PSA) (median=5, range 0.10–291 ng/mL), biopsy-proven prostate cancer, or both.
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The patients’ mean age was 64.2 years, ranging from 47 to 81 years old. Two patients
had undergone a partial radical prostatectomy, two patients had undergone hormone thera-
pies, two patients had received external beam radiation therapy (EBRT), four patients had
radiation seed implants, and one patient had received hormone therapy and EBRT. Data
from the eleven patients having undergone any form of treatment were not used in assess-
ment of contrast; however these data were included in visual and quantitative assessments
of distortion.
Thirty-nine of the fifty patients studied were untreated and considered for inclusion in
the study of contrast. Of these patients, ten were scanned with inconsistent MR parameters
during initial trials of this study and were not considered for the studies of ADC values. The
ADC value in presumed healthy peripheral zone tissue was assessed in the resulting twenty-
nine patients. Within this group of twenty-nine patients, twelve had no positive biopsy on
record. The seventeen remaining patients’ data were used to calculate the contrast between
tumor and healthy tissue for both FULL and rFOV sequences. Fourteen of these patients
exhibited a Gleason score of 3+3. One patient each presented with Gleason scores of 3+4,
3+5, and 4+3.
All images were acquired using a 3T MR scanner (GE Healthcare, Waukesha, WI, USA)
equipped with an eight-channel phased-array for the pelvis and an endorectal coil encased
in a balloon probe (Bayer Healthcare, Warrendale, Pa, USA). A perfluorocarbon compound
(3M, St. Paul, MN, USA) was used to inflate the balloon probe to reduce artifacts due to
susceptibility [17].
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Anatomic imaging was provided by oblique axial T2-weighted images (512x512, TR/TE =
6350/103 ms). FULL (128x128, FOV=24cm x 24cm, NEX=4, TR/TE = 4000/78–90ms, 2:44
minutes) and rFOV (128x64, FOV=18cm x 9cm (n=37) or 24cm x 12cm (n=13), NEX=6,
TR/TE = 4000/78–90ms, 2:52 minutes) DWI sequences were acquired using a 2D single-shot
EPI (ss-EPI) spin-echo sequence with receiver bandwidth = 250kHz, b = 600 and 0 s/mm2,
and 3mm slices (n=37) or between 3mm and 4 mm slices (n=13). Parallel imaging was used
in the FULL sequence, with an acceleration factor of 2. The rFOV acquisition employed a
2D spatially-selective echo-planar RF pulse in place of conventional excitation in the ss-EPI
sequence. The RF envelope of the 2D echo-planar pulse (∼18 ms duration) is minimum
phase by design so the echo time occurs toward the end of the pulse. Because of this, and
the fact that the spacing between the 90◦ pulse and the following 180◦ pulse is dominated
by the diffusion weighting time, the RF pulse did not increase the echo time compared
to the conventional sequence. The time-bandwidth of the RF envelope (slice direction)
was relatively small, therefore the slice dephasing from the non-linear phase excitation was
relatively benign. The TE varied among patients due to changes in obliquity of the prostate
and therefore, the scan prescription. The phase-encoding direction, and consequently the
reduced-FOV axis for the rFOV DWI scan, was in the oblique anterior-posterior direction.
The DWI images were obtained with slice locations and obliquity identical to the oblique axial
T2-weighted images. Thirteen patients were scanned with the rFOV sequence acquired with
FOV = 24cm x 12cm and the slice thickness greater than 3 mm during initial testing. These
patients’ data, acquired with inconsistent MR parameters, were used in the quantitative
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and visual assessments of distortion. Although ten of the thirteen patients presented with
radiologist-identified tumor regions, the data were not used in the study of contrast to avoid
any bias due to different partial-voluming effects. Under the assumption that prostate tissue
is isotropic, ADC maps were computed from the combined DWI and T2-weighted reference
images using Eqn 1.10.
The incidence and severity of visually assessed distortion was characterized by changes
in the contour of the prostate adjacent to the rectal wall. The rFOV and FULL ADC maps
were scored 0 for no distortion, and 1–4 for increasing distortion. A distortion score of 0
reflects no visible change in the boundary between prostate and rectum in comparison to
a T2-weighted image. A distortion score of 1 reflects slight disturbances in the boundary
region, whereas a distortion score of 2 is appropriate for more extensive disturbances in the
boundary, or specific regions of high susceptibility artifact. A distortion score of 3 denotes a
consistently distorted prostatic boundary, with some areas in the prostate unusable due to
susceptibility artifact, and a distortion score of 4 is used to describe a prostate image that is
entirely unusable due to susceptibility artifact. Examples of each distortion score are shown
in Figure 2.1. All distortion scores were assigned by three independent observers to control
for inter-observer variability. T2-weighted oblique axial images were used as a reference of
no distortion.
A quantitative method of measuring distortion was also performed by comparing the radii
of circles that reflect rectal wall curvature adjacent to the prostate. The inflated endorectal
probe creates a reliably circular rectal shape on oblique axial images, and deviation from
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Figure 2.1: Distortion scores from sample patients showing A score of 0, B score of 1,
C score of 2, D score of 3, E score of 4, and F a guideline of visual score interpretation.
Please note that E contains artifact that has rotated the prostate signal, rendering spatial
localization unusable.
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the circular pattern is a typical sign of susceptibility-induced distortion. On FULL, rFOV,
and T2-weighted images, the radius of the largest circle tracing the rectum adjacent to the
prostate, and without covering the rectal wall, was recorded on three slices. These three
selected slices were equally spaced throughout the prostate—in the base, midgland, and
apex—and matched in location among image types. The percent difference of the rectal wall
radius on the FULL and rFOV ADC maps from the corresponding radius on the T2-weighted
image was calculated for each of the three slices. These values were averaged within each
patient to create a quantitative distortion measure of each DWI sequence for each patient.
Regions of interest (ROIs) were placed in areas of presumed healthy peripheral zone tissue
in the group evaluated for assessment of healthy ADC values. ROIs were also placed in areas
of reduced ADC corresponding to suspected tumor regions and in areas of presumed healthy
contralateral tissue in each patient included in the study of contrast. Suspected tumor
regions were identified as regions of both positive biopsy findings and radiologist-identified
tumor in the MR exam. For patients with more than one biopsy-proven tumor region, the
most aggressive tumor region was used to calculate contrast. For a given patient, all tumor
ROIs and control ROIs were the same size within one pixel, and ranged between 0.143 and
0.642 cm2. ROIs for all patients were drawn by a single researcher to avoid inter-observer
variability. Tumor contrast was calculated using Eqn 2.1:
Contrast =
∣∣∣∣∣ADCtumor − ADChealthyADChealthy
∣∣∣∣∣ (2.1)
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Statistical analyses were performed using JMP V10 software (SAS Institute, Cary, NC,
USA). A Wilcoxon signed-rank test was performed to assess significant differences between
FULL and rFOV distortion scores for each observer. The difference in distortion scores
between FULL and rFOV images for each patient was compared among the three observers
using a Kruskal-Wallis test. As a quantitative distortion assessment, differences in rectal
curvature were tested by student’s t-tests. Differences in tumor, healthy tissue, and tumor-
to-healthy-tissue contrast in FULL and rFOV scans were also tested for significance using
student’s t-tests. Tests for normalcy were done using Shapiro-Wilk tests.
2.3 Results
Forty-nine of the fifty patients (98%) assessed showed rectal wall distortion interfering with
the peripheral zone of the prostate on either the FULL or rFOV sequence by at least one
observer. Examples of each distortion score are shown in Figure 2.1. Distortion scores were
significantly reduced with the rFOV sequence (p=0.012 Wilcoxon signed-rank tests, n=50).
Significance and average difference between sequences scored by each observer are shown in
Table 2.1. The measured difference between FULL and rFOV distortion for a given patient
did not vary significantly among observers (p=0.99, Kruskal-Wallis test, n=50 counts per
group, 3 groups). The quantitative measure of distortion—the average percent difference in
rectal wall radii between the ADC maps and the T2-weighted images—also demonstrated
lower distortion with the rFOV sequence than the FULL sequence. The average percent
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Table 2.1: Wilcoxon signed-rank tests for difference in distortion scoring among patients
show a significant decrease in observed distortion in ADC maps created from the reduced-
Field-of-View (rFOV) sequence compared to the conventional (FULL) sequence for each
observer (n=50). The average decrease in distortion score is similar for all observers, p=0.99,
Kruskal-Wallis test, SD = standard deviation.
Observer rFOV Improvement FULL - rFOV Difference
(0-4 Scale) (Average ± SD)
1 p=0.0063 0.56± 0.68
2 p=0.0117 0.48 ± 0.61
3 p=0.0010 0.52 ± 0.65
difference in rectal wall radii compared to T2-weighted reference images was significantly
lower for rFOV ADC maps (26 ± 10%) than for FULL ADC maps (34 ± 13%) (p=0.011,
n=50, student’s t-test).
A typical distortion case (Figure 2.2) shows a patient whose rectal wall signal has merged
with the medial prostate peripheral zone signal, drastically distorting the entire prostate
border and the periphery of the tumor on the FULL ADC in this region. This patient had
an average distortion score of 2.67 on FULL ADC and 1.33 on rFOV ADC and a percent
difference of rectal wall radii of 50.8% on FULL ADC and 21.8% on rFOV ADC. A second
example case (Figure 2.3) shows either blood or fecal matter as dark lobules in the rectal
wall with localized susceptibility artifact on the FULL ADC map demonstrating an average
distortion score of 2.33. These distortions are greatly reduced on the rFOV ADC map, with
an average distortion score of 1. The quantitative distortion measure yielded 20.1% percent
difference on the FULL ADC map and 14.8% on the rFOV ADC map.
All reported ADC values (measured by units of 10−3mm2/s) and ADC contrast values
were normally distributed across the studied population (Shapiro-Wilk Tests). The average
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Figure 2.2: Oblique axial images of A FULL ADC map, B rFOV ADC map, and C
T2-weighted image for a patient with a visible tumor in the left peripheral zone (dashed
arrows). The boundary of the rectum and peripheral zone (solid arrow) is distorted in the
FULL image, less so in the rFOV image, and not at all in the T2-weighted image. This is
a patient with a negative biopsy and recently elevated PSA of 2.0, on active surveillance at
the time of this scan.
Figure 2.3: Oblique axial images of A FULL ADC map B rFOV ADC map and C T2-
weighted image at the base of the prostate near the bladder (dashed arrow) for a patient
with blood or fecal artifact visible at the rectum/peripheral zone interface (solid arrows).
This is a patient with a positive biopsy showing Gleason Score 3+3, on active surveillance
at the time of this scan.
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Table 2.2: Conventional full-Field-of-View sequence (FULL) and reduced-Field-of-View se-
quence (rFOV) apparent diffusion coefficient (ADC) values [10−3mm2/s] and contrast [%] for
untreated patients with identified tumor (n=17). ADC values show no statistical difference
between healthy tissue in tested sequences (p=0.978) and a trend towards lower ADC values
in tumor regions using rFOV (p=0.0854).
Acquisition Tumor ADC Healthy Tissue ADC Contrast (%) Significance
Full 1.022 ± .185 1.620 ± .231 35.9 ± 13.2
rFOV 0.952 ± .180 1.731 ± .230 44.0 ± 13.3 p=0.0012
ADC in healthy tissue for the twenty-nine untreated patients was 1.616 ± 0.399 for the
FULL and 1.733 ± 0.223 for the rFOV, which were not significantly different, p=0.754.
For the seventeen patients included in the study of tumor contrast, the rFOV sequence
provided significantly higher absolute value of the contrast between tumor and healthy tissue
(average contrast = 44.0%) than the FULL sequence (average contrast = 35.9%) (p=0.0012,
n=17, student’s t-test). ADC values for tumor and healthy tissues with corresponding
contrast values are listed in Table 2.2 for this group of patients. For the FULL and rFOV
sequences, the ADC values in the healthy tissue of the untreated patients presenting with
tumor were not significantly different (p=0.9782, n=17, student’s t-test). However, the
intensities of the tumor regions in the rFOV ADC maps had a trend to be lower than the
corresponding tumor regions in the FULL ADC maps (p=0.0854, n=17, student’s t-test).
2.4 Discussion
This study demonstrated that an alternate DWI acquisition scheme, based on using a pulse
sequence with reduced-FOV excitation, provided significantly less image distortion and sig-
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nificantly improved contrast between tumor and healthy tissue ADC compared to a conven-
tional DWI sequence acquired with a full phase-direction FOV. To the best of our knowledge,
this is the first study to compare either susceptibility-related distortion or tumor contrast in
prostate DWI utilizing conventional- and reduced-FOV DWI acquired in the same exam.
It must be noted that the patient population in this study was enrolled regardless of
Gleason score, and as a result does not adequately represent a range of tumor aggressive-
ness. Regardless, the FULL ADC values measured in this study in tumor (mean = 1.00
± 0.52x10−3 mm2/s) and healthy tissue (mean = 1.61 ± 0.40x10−3 mm2/s) were similar to
those from other studies, which had healthy values ranging from 1.59 ± 0.04x10−3 mm2/s to
1.75 ± 0.23x10−3 mm2/s [41] [86] and tumor values for Gleason Score = 6 disease ranging
from 0.86 ± 0.04x10−3 mm2/s to 1.3 ± 0.30x10−3 mm2/s [87] [88]. Absolute contrast mea-
sures between tumor ADC and healthy tissue ADC were also similar to the values from the
literature, which were estimated to be in the range of 28% to 40% [34].
Because the implementation of the rFOV technique in this study allows a higher im-
age resolution compared to the FULL sequence while maintaining clinically-applicable scan
times, the technique also decreases partial voluming effects in heterogeneous tissue. The
reduced partial volumning and the reduced distortion near tissue interfaces may be partially
responsible for the observed significant increase in image contrast between tumor and healthy
tissue in the rFOV sequence in comparison to the FULL sequence.
Other acquisition schemes that reduce the number of phase encoding steps could result
in reduced distortion for EPI DWI. However, such methods result in either aliasing in the
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image, or require a very large FOV to span the body, resulting in poor spatial resolution.
The sequence described in this work uses a pulse sequence incorporating a rectangularly-
selective excitation, which enables us to attain a FOV smaller than the body size in the
phase-encoding direction, thus achieving high spatial resolution.
Recently, there have been several published works using various rectangularly-selective
DWI approaches to improve spatial resolution or increase image quality for optic nerve,
spine, and prostate imaging [89] [90] [91], which are fundamentally different from the rFOV
sequence tested in this study due to the usage of non-coplanar RF pulses. One such modified
DWI acquisition technique was recently evaluated to increase the quality of prostate DWI
for the purposes of tractography [90]. This technique is the zonal oblique multi-slice diffusion
tensor imaging (ZOOM) DTI sequence, which uses tilted non-coplanar RF pulses to refocus
spins contained in the imaging slice. This sequence was developed to perform DWI in the
presence of large volumes of fat and unpredictable motion and has demonstrated significant
improvement in DWI images of the optic nerve [89]. A drawback of the technique is that
the non-coplanar pulses leave residual signal in the imaging plane adjacent to the imaged
slice. For multi-slice imaging, utilizing this method requires either increasing the gap be-
tween slices to avoid unwanted excitation in the imaging plane, or increasing scan time to
ensure imaged tissue is fully relaxed before acquiring each slice, making this method most
effective in imaging one-dimensional anatomy, as in the optic nerve. The evaluation in the
prostate utilized a smaller FOV and higher spatial resolution than the conventional diffusion
technique. ZOOM DTI provided a greater number of fibers detected and more homogeneous
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fat saturation but did not result in a reduction in prostate image distortions in the small
patient population. In contrast, in this study we demonstrate a significant reduction in
prostate DWI image distortion with the rFOV technique compared to the FULL sequence.
Another, similar technique to reduce the FOV in MR of the prostate using outer volume
suppression has been presented by Reischauer et al. [91]. This research measured ADC per-
formance for prostate cancer detection showing high accuracy (73.5%), specificity (75.2%),
and sensitivity (70.4%) in comparison to biopsy, but did not compare the ADC obtained
from the novel technique with ADC from the conventional technique to assess the impact
on distortion. As both this study and ours reduce the number of phase encoding steps
acquired, both are apt to reduce susceptibility artifact in the images, and their study did
report attaining high quality images. However, the outer volume suppression method excites
tissue adjacent to the imaged slice similar to the ZOOM DTI method, again requiring either
increased slice gap or wait time for relaxation. While likely similar in reducing distortion
artifact, our study used a 2D, echo-planar RF refocusing pulse [85], which does not excite
adjacent tissue, to achieve the reduced-FOV enabling multi-slice imaging without requiring
increased scan time or slice gap. However we did not perform a direct comparison to this
technique and thus cannot compare the image quality.
The pulse sequence used in our research study has been previously demonstrated to
enable high spatial resolution and qualitatively increase image quality in breast DWI [92]
and pancreatic DWI [93]. These studies demonstrated that the mean ADC of tumor regions
was not significantly different between rFOV and FULL DWI. However, the minimum ADC
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value of a tumor region was found to be significantly lower in the rFOV sequence in the breast
study [92]. These findings are consistent with our results that demonstrated qualitatively
and quantitatively increased image quality and non-significant differences between the ADC
values of the FULL and rFOV sequences with a trend toward lower tumor ADC values for
rFOV than the FULL sequence. The pancreatic study [93] found no difference between ADC
values in FULL and rFOV DWI images, however the sequence was designed to maximize
the image quality in favor of increasing contrast. Although these studies represent potential
for rFOV DWI in a variety of organs, our study investigated the unique scenario of imaging
a thin band of tissue of interest (the peripheral zone) adjacent to tissue with potentially
drastically different magnetic susceptibility (air, fecal matter, or blood in the rectum), prone
to severe distortion artifacts.
In spite of the sharp excitation profile in the phase encoding direction from the high
time-bandwidth 2D RF pulse used in the rFOV sequence [85], in our particular application,
signal in the transition band from the very high fluid signal along the rectal wall—such as a
perineal hernia—can cause serious wrapping artifact. There is risk of such signal wrapping
into the central gland of patients with very large prostates. This is particularly limiting to
patients who suffer from benign prostatic hyperplasia, which increases PSA and prostate size,
typically leading to clinical testing for prostate cancer staging. Encoding a slightly larger
FOV than the excited FOV extent or adding a saturation band to the oblique posterior of
the prostate can prevent this artifact.
One limitation of this study is the measures were user dependent in scoring the distor-
49
tion, in identifying corresponding slices, and in visually matching circles to the rectal wall.
However, the changes in visual scores between the FULL and the rFOV sequences were very
similar among the three readers, and both the visual scoring and the quantitative measures
of rectal wall distortion yielded similarly significant reduction in distortion with the rFOV
sequence compared to the FULL sequence. These results lend confidence to our conclu-
sion that the rFOV sequence results in less image distortion on ADC maps than the FULL
sequence.
Another limitation of this study is the use of a single, non-zero b-value in all patients
with comparison to a b=0 image. Our ADC values may differ from those obtained using a
non-zero reference image. Although there is no consensus on the optimal b-value for prostate
cancer detection, in addition to the moderate b-value we used (b=600), studies have shown
relevance for high-b-value acquisition for detection of prostate cancer [94] [95]. At higher
b-values, the rFOV DWI acquisition would require increased averaging to boost the SNR,
increasing scan time. Due to scan time constraints in the present study, rFOV DWI at higher
b-values was not acquired in this work but will be explored in the future.
Despite the limited scope of our study, the distortion due to susceptibility artifact was sig-
nificantly lower in the rFOV sequence than in the comparable FULL sequence. Additionally,
the rFOV technique employed has been shown to increase contrast between biopsy-proven,
radiologist-identified tumor regions and healthy contralateral tissue. This is particularly im-
portant, as the ADC map intensity may correlate with tumor grade in prostate cancer [34].
Increasing tumor contrast may increase the value of using the ADC map for both detecting
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prostate cancer and assessing its grade.
In conclusion, the rFOV sequence yielded significantly decreased rectal wall suscepti-
bility artifact and provided significantly higher contrast in ADC value between tumor and
healthy tissue as compared to the FULL sequence without significantly increasing scan time.
This technique shows great promise for improving DWI quality, potentially improving the
detection of prostate cancer by MRI.
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Chapter 3
Distinguishing Inflammation from
Low-Grade Prostate Cancer in the
Peripheral Zone of the Prostate
Abstract
Inflammation is a common confounder on prostate MRI, mimicking low-grade prostate cancer
in the peripheral zone (PZ). The purpose of this study was to develop a model to distinguish
inflammation in the PZ of the prostate from normal PZ tissue and low-grade prostate cancer
using an optimized combination of multiparametric MRI (mpMRI) parameters. Eighteen
patients with pathologist-defined regions of normal PZ tissue, inflammation, and low-grade
prostate cancer, underwent a 3T mpMRI including T2-weighted imaging, diffusion-weighted
imaging, dynamic contrast-enhanced (DCE) MRI, and 3D 1H spectroscopic imaging. Re-
gions of interest were transposed from whole-mount pathology onto T2-weighted images and
propagated to functional maps created from the mpMRI. A depth-restricted decision tree
was built to select the most distinguishing features, and to provide an implementable outline
for radiologists. A tree built on apparent diffusion coefficient (ADC) and DCE maximal
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enhancement slope correctly classified 79.6% of 54 regions as cancer, inflammation, or nor-
mal PZ tissue. In Wilcoxon rank sum tests, mean ADC in normal PZ tissue (1.49±0.23
10−3mm2/s) was significantly higher than that of inflammation (1.11±0.24, p<0.01) and
low-grade prostate cancer (1.11±0.21, p<0.01). Inflammation and low-grade prostate cancer
were not distinguishable by ADC alone (p=0.95). However, low-grade prostate cancer had
significantly faster maximal enhancement slope on DCE (1.24±0.41 enhancement over pre-
vious timepoint) than inflammation (0.77±0.28, p<0.01) and normal PZ tissue (0.90±0.36,
p=0.02). Inflammation and normal PZ tissue were not distinguishable on DCE maximal
enhancement slope (p=0.57) alone.
3.1 Introduction
Multiparametric MRI (mpMRI) is a powerful noninvasive technique for the staging of prostate
cancer [96] [97], and is increasingly included in clinical management of patients in the United
States [98] [99] and abroad [100] [101]. The number of tissue properties that can be probed
by mpMRI in a single exam can improve the characterization of prostate cancer: T2-weighted
imaging for anatomic differentiation, diffusion-weighted imaging (DWI) to measure cellular-
ity, dynamic contrast-enhanced MR imaging (DCE MRI) to assess differences in the gland’s
perfusion and tissue structure, and 1H-MR spectroscopic imaging (1H-MRSI) to examine
differences in metabolite concentrations.
Prostate cancer typically occurs in the presence of heterogeneous benign tissues, which
can complicate the ability of mpMRI to identify and assess the presence, extent and ag-
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gressiveness of prostate cancer [33] [102]. Inflammation in the prostate is suspected to be a
major cause of false positive MRI readings [103] [104] [105], and its characterization of re-
duced signal on T2-weighted imaging [106] and apparent diffusion coefficient (ADC) maps is
noted in the current version of the Prostate Imaging and Reporting Data System (PI-RADS
v2) [13]. In the peripheral zone (PZ), where 70% of prostate cancer is located, inflammation
presents with low signal intensity on ADC maps [107]. ADC value scales inversely with
prostate cancer grade, and inflammation overlaps to a large extent with low-grade prostate
cancer [13].
PI-RADS v2 also cites that inflammation in the PZ can present as a false positive on
DCE MRI due to increased perfusion, where a positive DCE MRI finding is defined as early
or focal enhancement compared to normal adjacent tissue. However, PI-RADS v2 also notes
that assessment of DCE MRI could be enhanced by the creation of parametric maps [13].
Common parametric maps include peak enhancement, time to peak enhancement, and max-
imal enhancement slope. Fully quantitative metrics, such as the transfer constant from the
blood plasma to the extracellular space (Ktrans), can be robust to patient perfusion differ-
ences but rely on arterial input quantification and pharmacokinetic modeling. Inflammation
can also confound 1H-MRSI by presenting with elevated choline in comparison to normal
tissue in the peripheral zone, statistically indistinguishable from regions of prostate can-
cer, however this metabolic signature is shared with other confounders such as high-grade
prostatic intraepithelial neoplasia [76] [105].
The purpose of this study was to create a model for the prostate PZ for distinguishing
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inflammation from both normal tissue and low-grade prostate cancer using an optimized
combination of mpMRI parameter maps, using whole-mount section pathology as the refer-
ence standard.
3.2 Materials and Methods
This study was approved by the Committee on Human Research at this institution and
was compliant with the Health Insurance Portability and Accountability Act. Written,
informed consent was obtained from all 18 subjects. After whole-mount resection of the
prostate, a pathologist characterized regions of cancer by Gleason grade, as well as regions
of inflammation, atrophy, benign prostatic hyperplasia, high-grade prostatic intraepithelial
neoplasia, and normal PZ tissue.
Patients with clear-cut regions of low-grade cancer (Gleason 3+3 or Gleason 3+4), of
inflammation, and of normal tissue in the PZ identified at the post-surgical whole-mount
pathology reading were included in this analysis. Pathological inflammation was defined as
5% or greater infiltration of lymphocytes into the tissue and assumed to be chronic; there
were no patients with evidence of acute inflammation enrolled in this study. The patient’s
mean age at time of scan was 63.9±5.8 years. The average PSA in this population was
5.1±1.8 ng/mL, with 5 patients presenting with a Gleason Score of 3+3 and 13 patients
presenting with a Gleason Score of 3+4 at the time of surgery.
Patients received a 3T multiparametric MRI of the prostate (GE Healthcare, Waukesha
WI, USA) with a GE pelvic phased coil array and a flexible balloon endorectal coil (Medrad,
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Inc., Indianola PA, USA). Anatomic imaging was performed using a T2-weighted fast spin-
echo sequence with FOV = 18 cm, slice thickness = 3mm, matrix = 512 x 512, and TR/TE =
6000/96 ms, prescribed at an obliquity matching the posterior edge of the prostate. Anatomic
images were intensity-corrected for the endorectal coil profile [19].
Functional imaging (DWI, DCE MRI and 1H MRSI) was performed at the same obliquity
and slice thickness as the anatomical T2-weighted sequence. Six-direction diffusion-weighted
imaging (DWI) was acquired using a 2D single shot spin-echo sequence with a b-value of
600 s/mm2, FOV = 18 cm, TR/TE = 4000/(minimum full TE) ms, slice thickness = 3mm.
Additionally, in 7/18 patients, high b-value DWI was acquired using a 2D single shot spin-
echo sequence with a b-value of 1350 s/mm2, FOV = 26 cm, TR/TE = 4000/(minimum full
TE) ms, slice thickness = 3mm. DCE MRI was acquired using a single dose of gadopentatate
dimeglumine (Magnavist, Bayer Inc.) injected at 2 mm/sec with total injected amount
determined by patient body weight. DCE MRI used a 3D fast SPGR sequence with a
temporal resolution of 10.4 seconds, FOV = 46 cm, TR/TE = 3.5/0.9 ms, flip angle =
5o, with 5 timepoints acquired before injection to establish a baseline for semi-quantitative
metrics. 1H-MRSI was acquired using 3D PRESS with TR/TE = 2000/85 ms, resolution =
5.4x5.4x5.4 mm, NEX=1.
An apparent diffusion coefficient (ADC) map was created from the DWI sequence using
in-house software that creates a geometric mean of the images using b=600 s/mm2 and,
under the assumption that prostate tissue is isotropic, calculates ADC value per voxel ref-
erencing a T2-weighted b=0 s/mm
2 image. For the 11 patients for which no high b-value
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DWI was acquired, an averaged high b-value (b=1350 s/mm2) DWI was calculated based
upon the lower b-value images, assuming a monoexponential decay. Parametric maps of
peak enhancement value, time to peak enhancement, maximal enhancement slope, and av-
erage washout slope were created from DCE MRI. Peak value is defined as the maximum
intensity reached over the time-course divided by the baseline signal intensity; time to peak
enhancement is the discrete time point when the enhancement first reaches 90% of the max-
imum; maximal enhancement slope is defined as the greatest increase in intensity between
any two timepoints; washout slope is the slope from a linear fit to the enhancement curve
from the peak through to final timepoints [108]. Metabolic maps from the 0.16 cc resolution
1H MRSI prostate spectra were created based on the integrated areas under the curves for
the metabolites choline, creatine, and citrate, and intensity-corrected for the endorectal coil
profile [19].
To characterize the MR-measured differences between tissue classes, while avoiding over-
fitting to our small sample size, a decision tree classifier restricted to a maximum depth of
two was trained on the full dataset to provide easily translatable guidelines to the clinic.
Post hoc Wilcoxon rank sum tests were used to quantify the statistical differences between
prostate tissue types.
3.3 Results
Eighteen patients presented with regions of inflammation, low-grade prostate cancer, and
normal PZ tissue, resulting in 54 regions to train a decision tree. Figure 3.1 shows a visual
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Figure 3.1: The resulting decision tree classifier based on 54 regions of inflammation,
low-grade prostate cancer, and normal peripheral zone tissue, constrained to a max depth of
two. Signal intensity on the apparent diffusion coefficient (ADC) map created from diffusion-
weighted imaging, and on the map of maximal wash-in slope by DCEMRI, correctly classified
80% of all regions and 67% of regions with inflammation.
depiction of the tree structure, which correctly classified 79.6% of the 54 samples as low-
grade prostate cancer, inflammation, or normal PZ tissue. Two regions of inflammation and
one region of normal PZ tissue were incorrectly classified as low-grade prostate cancer; only
one region of low-grade prostate cancer and one region of normal PZ tissue were classified
as inflammation. The decision path for identifying normal PZ tissue had two branches, for
high and low maximal enhancement slope, both of which included a decision based on a high
ADC value. Using these criteria a total of two regions of low-grade prostate cancer and four
regions of inflammation were classified as normal PZ tissue.
ROIs were not normally distributed within tissue types (Shapiro-Wilk tests); Wilcoxon
rank sum tests were used for post hoc analysis. Intensity ranges for the ADC value and
the maximal enhancement slope for normal PZ tissue, regions of inflammation, and low-
58
grade prostate cancer are shown in Figure 3.2. ADC in normal PZ tissue was significantly
higher than that of inflammation (p<0.01), and significantly higher than that of low-grade
prostate cancer (p<0.01). However, inflammation and low-grade prostate cancer were not
distinguishable by ADC value (p=0.95). Maximal enhancement slope values (measured as
enhancement over previous timepoint) in regions of inflammation were not distinguishable
from in regions of normal PZ tissue (p=0.57). Regions of low-grade prostate cancer had a
significantly faster maximal enhancement slope than both normal PZ tissue (p=0.02) and
inflammation (p<0.01). Images from a representative patient with Gleason 3+4 low-grade
prostate cancer and a contralateral region of inflammation are shown in Figure 3.3.
We can see that both a region of low-grade prostate cancer denoted by a solid arrow,
and a region of inflammation denoted by a striped arrow, are distinguishable from normal
PZ tissue by reduced signal on ADC (B). Low-grade prostate cancer is distinguishable from
inflammation and normal PZ tissue by increased maximal enhancement slope on DCE MRI,
and inflammation is indistinguishable from the normal PZ (C).
ADC was reduced in 17/18 regions of inflammation, and all regions of cancer, compared
to normal PZ tissue in a given patient. ADC in both regions of cancer and regions of
inflammation was, on average, reduced by 24% compared to normal PZ tissue from the
same patient. Maximal enhancement slope was higher in cancer compared to normal tissue
in 15 of 18 cases, on average elevated 54%. Regions of inflammation were comparable to
normal tissue within patients, with higher maximal enhancement slope in 8 cases and lower
maximal enhancement slope in 10 cases. Regions of inflammation showed an average maximal
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Figure 3.2: Summary of average signal intensities and significances between normal pe-
ripheral zone tissue (Normal PZ), inflammation, and low-grade prostate cancer (Low Grade
PCa) in the 54 regions studied on the apparent diffusion coefficient (ADC) map created
from diffusion-weighted imaging (10−3mm2/s), and on the map of maximal wash-in slope by
dynamic contrast-enhanced (DCE) MRI (enhancement over previous timepoint).
enhancement slope <1% different from regions of normal PZ tissue in the same patient. In
all but one case, maximal enhancement slope in regions of inflammation was lower than in
regions of cancer within the same patient. Average enhancement per tissue type over time
is presented in Figure 3.4.
Other imaging metrics showed significances and trends between the tissue types, but
were withheld from our depth-restricted model to avoid overfitting. Inflammation showed
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Figure 3.3: A representativeA T2-weighted image, B ADC map, andC DCEMRI maximal
enhancement slope map showing a region of Gleason 3+4 low-grade prostate cancer (solid
arrows) with reduced T2 signal intensity, reduced ADC, and increased maximal enhancement
slope. The region of inflammation (striped arrows) shows normal T2 signal intensity, with
reduced ADC, and no increase in maximal enhancement slope compared to the contralateral
normal PZ tissue.
significantly lower signal on traditional T2-weighted imaging compared to normal PZ tis-
sue (p<0.01), and was not significantly different than low-grade prostate cancer (p=0.16).
Washout slope in regions of low-grade prostate cancer was significantly faster than in normal
PZ tissue (p<0.05) and non-significantly faster than in regions of inflammation (p=0.24).
Compared to normal PZ tissue, low-grade prostate cancer showed an average of 26%±27%
higher levels of choline, and regions of inflammation showed an average of 19%±39% lower
levels of choline; none of these differences were significant. Both regions of inflammation and
of low-grade prostate cancer had lower levels of creatine (39%±11% and 20%±40% reduced,
respectively) and lower levels of citrate (73%±230% and 46%±19% reduced, respectively)
than that of normal PZ tissue, but only the low citrate in regions of inflammation was
significantly lower than that of normal PZ tissue (p=0.018). Regions of inflammation had
lower levels of all three metabolites in comparison to low-grade prostate cancer and normal
PZ tissue.
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Figure 3.4: DCE MRI results per timepoint, showing mean and 95% CI of signal intensity
per tissue type, and normalized to the baseline signal intensity and injection time. We see
tissue with inflammation demonstrating behavior remarkably similar to normal PZ tissue,
with low-grade prostate cancer showing faster uptake.
3.4 Discussion
In this study we investigated patients with a 1H mpMRI exam prior to radical prostatectomy
with whole-mount histopathologic-identified inflammation, low-grade prostate cancer, and
normal tissue in the PZ. Standard of care histopathologic assessments typically provide
information about the presence, extent, and aggressiveness of cancer, but rarely report the
presence and extent of confounding factors such as inflammation, which can significantly
impact cancer identification on a 1H mpMRI exam. The most significant finding of this
study is that chronic inflammation in the peripheral zone of the prostate, histopathologically
assessed by the presence of lymphocytes in tissue, can be quantitatively distinguished from
both normal PZ tissue and low-grade prostate cancer using a combination of the ADC and
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the maximal enhancement slope values on DCE MRI, acquired as part of standard mpMRI
prostate cancer exams being acquired around the world [98] [99] [101]. These quantitative
DWI and DCE MRI results can be used in combination with the more qualitative PI-RADS
v2 interpretation of prostate cancer presence to improve the assessment of presence and
extent of prostate cancer at diagnosis, improving therapeutic selection for individual patients.
Inflammation in the prostate normally presents as acute or chronic. Chronic inflammation
is the more likely clinical scenario for patients going on for active surveillance and more
aggressive interventions such as surgery or radiation [109]. In our work, no patients were
diagnosed with acute prostatitis, therefore the findings pertain to chronic inflammation,
whereas most published data [110] [111] references acute inflammation.
Other works [107] [110] have found differences in the ADC value of inflammation com-
pared to normal PZ tissue and prostate cancer, however the definitions of cancer, inflam-
mation, and normal tissue differ in these works. One study found regions of inflammation
indistinguishable from normal PZ tissue on ADC, however the normal PZ tissue values were
biopsy-confirmed benign regions from radiologist-defined cancer-suspicious regions on MR
[107]. This suggests that other confounding benign pathologies such as atrophy, HGPIN,
and BPH could have been present in their normal PZ tissues, and explains why regions of
inflammation would appear similarly in ADC value. A study comparing inflammation to
all grades of prostate cancer, lowering the average ADC value for prostate cancer, found
significantly lower ADC values in prostate cancer compared to regions of inflammation [110].
Similarly, there have been consistent findings in DCE MRI studies of inflammation; how-
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ever, the semi-quantitative metrics extracted from these studies differ between groups. In a
study of 38 needle biopsy samples of inflammation from 178 men after DCE MRI as part of
an mpMRI of the prostate, regions of inflammation enhanced in the early part of DCE MRI,
similar to prostate cancer, potentially resulting in a false positive radiologic reading [111].
Likewise, in 50 patients studied by whole-mount histopathology after mpMRI, 9 regions of
inflammation showed early enhancement with a heterogeneous appearance, similar to regions
of prostate cancer [110]. In these works, along with PI-RADS v2 [13], the most commonly
referenced metric extracted from DCE MRI is early enhancement.
In this work, we show DCE MRI distinguishing inflammation from prostate cancer, con-
trary to the above. While regions of inflammation in our data have higher initial enhance-
ment than regions of normal PZ tissue, similar to cancer and described in the above works,
it’s the behavior of enhancement—characterized by the maximal enhancement slope—that
distinguishes regions of inflammation from regions of low-grade prostate cancer. The differ-
ences in presentation could also be explained by different types of inflammation in the tissue.
Acute inflammation is a call to repair, characterized by leaky vasculature and an influx of
lymphocytes, and we would expect increased and early enhancement. However, in chronic
inflammation, the vasculature is normal, leading to a normal enhancement slope.
There were several limitations to this study, primarily that the small number of subjects
prevents us from reliably extrapolating these findings to a wider population. A larger study
could determine numeric cutoffs for the ADC value and maximal enhancement slope that
separate inflammation from low-grade prostate cancer and normal PZ tissue with enough
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certainty to recommend to other sites. However, the strength of characterization and inter-
pretability in this small population suggests similar guidelines could be incorporated into
clinical practice.
A second limitation is that the numerical cutoffs are not directly applicable to other
sites or imaging protocols without calibration or use of fully quantitative parameters, such
as Ktrans, instead of maximum enhancement slope. While Ktrans is robust to differences in
patient perfusion, it requires the measurement or assumption of an arterial input function
and pharmacokinetic modeling, which may not be possible at all sites. The semi-quantitative
maps used in this study can quantify key characteristics of enhancement with limited post-
processing needs, while correcting for some patient and acquisition artifacts, but without
correcting for the baseline T1 values from the same tissue, or locating and modeling the input
at a lateral artery. Semi-quantitative maps, with their less-intensive post-processing needs
and fewer tissue parameters, yielded excellent tissue discrimination in this study. Ktrans
values could be used instead of the maximum enhancement slope, with different cutoffs, but
relative differences should hold within a patient whether using semi-quantitative or fully-
quantitative metrics.
In conclusion, inflammation in the PZ is characterized by lower ADC and comparable
maximal enhancement slope on DCE MRI compared to normal tissue. A combination of
ADC value and maximal enhancement slope on DCE MRI can distinguish regions of inflam-
mation from low-grade prostate cancer and from normal PZ tissue in the human prostate
with very good accuracy in this population. Considering the widespread presence of chronic
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inflammation in the human prostate, these results are promising for improving the differential
diagnosis of these tissues and should be explored further in larger patient populations. Future
versions of PI-RADS may consider defining a positive DCE MRI read by semi-quantitative
parametric maps, potentially expanding the role of DCE MRI for prostate tissue character-
ization.
66
Chapter 4
Multi-element, Multi-nuclear
Endorectal Coil for Development of a
13C, 1H-Multiparametric Magnetic
Resonance Imaging Exam of the
Human Prostate at 3T
Abstract
The mpMRI exam is increasingly used to determine if a patient has indolent low-grade versus
aggressive high-grade prostate cancer at biopsy diagnosis, and whether active surveillance or
aggressive treatment is required for each patient. However, the length of the current mpMRI
exam is a major limitation to widespread use, and the combined data cannot adequately
determine which tumors will progress and therefore require treatment. MR spectroscopic
imaging with hyperpolarized 13C can probe real-time tumor metabolism and correlates with
aggressiveness in murine models. The non-renewable hyperpolarization restricts signal re-
ception time, and current hardware cannot cover the full area of the prostate at a clinically-
valuable spatial resolution when acquired in patients. Improving hardware to allow parallel
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imaging for both proton- and carbon-sensitive sequences will decrease scan time, and tai-
loring RF coil elements’ size and location to that of the prostate gland can recover the
signal-to-noise ratio (SNR) inherently lost in acceleration. In this chapter, we propose a
multi-nuclear, multi-element endorectal coil (ERC) to mimic the geometry of the prostate,
increasing SNR and potential acceleration at the proton and carbon frequencies. Preliminary
data shows a three-element longitudinal array to offer the most acceleration while maintain-
ing SNR and penetration depth. As an ethical constraint, all design criteria must be met
without increasing the size of the current ERC.
4.1 Background and Significance
Prostate cancer is extremely prevalent, with diagnoses in 1 in 6 American men, but fatal
for only 12% of cases [112]. Because the risk of side effects from the aggressive treatment of
prostate cancer (surgery and radiation therapy) is high (77%) compared to the risk of short-
term progression of prostate cancer (20%), the accurate characterization of prostate cancer
at diagnosis remains an active area of research for the clinical management of individual
patients as well as for monitoring therapy [113]. Active surveillance has emerged as an
appropriate management technique for patients whose disease is likely indolent (small and
Gleason grade ≤ 3+3) [114]. New focal therapy approaches are being considered for men
with defined regions of intermediate risk prostate cancer (moderate size cancers that have
some secondary Gleason pattern 4) that can be identified on imaging [113].
These approaches to treating prostate cancer require the ability for clinicians to accurately
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identify the location, size and pathologic aggressiveness of often small regions of prostate
cancer. This is currently undertaken through a mpMRI exam [115]. Particularly important
for accurate representation of disease is a fine spatial resolution, which is limited by each
image’s SNR. In order to acquire sufficient spatial resolution in a clinically reasonable time,
particularly for the low SNR imaging sequences—1H-MRSI, DCE and DWI—the mpMRI
data is acquired using an ERC and a phased array of external surface coils [116]. The
ERC significantly increases signal within the prostate, and decreases signal obtained from
outside the prostate that contributes to noise [41]. Combining an ERC and phased-array
coils has proven to increase the SNR in prostate exams at 3T over nine-fold in comparison
to use of a phased-array alone [17]. However, the mpMRI with full diagnostic quality lasts
approximately 75 minutes, which can limit patient compliance and widespread use.
An additional metric of functional imaging has emerged to probe real-time metabolism
for metabolic markers of cancerous activity. Injecting pyruvate labeled with hyperpolarized
carbon [1-13C]pyruvate shows flux of clinically-relevant biomarkers that participate in the
Warburg Effect [77]: an increase in aerobic glycolytic metabolism in cancerous tissue. Pyru-
vate is the natural output of glycolysis, and in healthy tissue enters the TCA cycle, with its
C1-carbon converted to carbon dioxide (CO2) [117]. Pyruvate is also converted to alanine via
the enzyme alanine transaminase (ALT) to varying degrees in normal tissues. However, due
to a number of genetic and microenvironment changes associated with cancer development
and progression, a significant proportion of pyruvate is converted to lactate via the enzyme
lactate dehydrogenase [118]. Although increased energy in the form of ATP is created via
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TCA metabolism, cancer utilizes a high rate of glycolysis even in the presence of oxygen.
Dynamic nuclear polarization (DNP) creates preferential alignment in nuclear spins by
the Overhauser effect; by transferring spin polarizations from electrons to nuclei, increasing
signal intensity per element until the polarization relaxes [79]. In prostate cancer metabolism,
the preferred route to use this technology is in hyperpolarized 13C-labeled pyruvate. To
determine the impact of cancerous development on cellular metabolism, we can probe how
much [1-13C]pyruvate is converted to [1-13C]lactate versus how much is converted into 13C
bicarbonate and [1-13C]alanine by hyperpolarized 13C MRI. 13C is visible on MRI at 3T
at a frequency of ∼32 MHz [81], and by tuning an ERC to this frequency we can receive
signal during and after injection, where hyperpolarization increases the signal from 13C
by over 10,000 times [119] [120]. 13C experiences different chemical shielding in pyruvate,
lactate, and carbon dioxide, so the increased preference of cancer for increased glycolysis and
lactate production are observable by MRSI [79]. However, polarization for hyperpolarized
[1-13C]pyruvate decreases rapidly (at the T1 relaxation rate of the
13C labeled carbonyl in [1-
13C]pyruvate, approximately 60 seconds at a magnetic field strength of 3T) after dissolution
and injection in to a patient [120].
There are current ERC arrays that combine coils tuned for proton with a coil tuned
to another nucleus’ frequency. Inclusion of a 13C-sensitive coil in an ERC design creates
increased sensitivity to cancer diagnostics and staging, however all such currently designed
coils utilize single-element reception, limiting coverage and sensitivity of 13C signal reception
across the prostate. No existing ERC contains multiple elements at multiple frequencies,
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in spite of the unique potential of parallel imaging to improve spatial resolution for the
non-renewable hyperpolarized signal. While there is a design for a multi-element proton-
sensitive an ERC [121]—using two elements overlapping in the R/L plane to provide increased
sensitivity and parallel imaging capability, overlapping coils in the center of the prostate both
limits the width of the minor axis of each element, reducing penetration [122], and increases
the signal from the urethra, which runs through the prostate in the same plane. The healthy
urethra contains high amounts of glycerophosphocholine, which resonates in the region of
choline—a marker of prostate cancer [123] on 1H-MRSI. This design also limits acceleration
by using elements with similar sensitivity profiles, which increases the coil g-factor.
Precision medicine relies on diverse and correlative information on a patient’s disease state
to offer the most beneficial treatment options. For prostate cancer, the mpMRI exam con-
tributes anatomic and functional tumor information, but the exam length limits widespread
usage, and measuring increased rates of metabolic reactions associated with cancer presence
and progression cannot be acquired using the current mpMRI exam [124] [125]. Incorpo-
rating hyperpolarized 13C would allow real-time monitoring of metabolic flux within the
prostate [120]; however the spatial resolution of hyperpolarized 13C MRI data from the hu-
man prostate is still relatively coarse. The proposed research is significant because it will
improve signal reception of the ERC by both decreasing noise received from outside the
prostate gland and by enabling accelerated reception by geometrically-optimized parallel
imaging of regions within the prostate. This advancement in signal reception will allow ac-
celeration at the proton frequency, which has the potential to shorten any 3D sequence in
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the mpMRI [126] [127]. At our institution, anatomic T1-weighted, MRSI and DCE imaging
techniques are acquired in 3D. Additionally, 3D T2-weighted and 3D DWI sequences are now
offered by major MRI suppliers. Utilizing parallel imaging with an acceleration factor of at
least 2 will reduce the mpMRI exam time to less than one hour. Additionally, acceleration
can lead to acquiring current 13C MRSI in 8.5 seconds instead of 12 seconds, with the remain-
ing 3.5 seconds traded for increased spatial resolution to better assess cancer aggressiveness
and treatment response [120].
The focus of this research was to design and build a receive-only proton- and carbon
endorectal coil to provide increased SNR and imaging acceleration by optimizing element
geometry to the shape of the prostate. The hypothesis for this work, based on preliminary
data, is that creating an array in the longitudinal direction with elements tailored to prostate
shape will both increase SNR by excluding irrelevant tissues, and will allow for greater
disparity in signal profiles from individual elements, resulting in higher acceleration potential
and more homogeneous coverage.
While the proposed ERC will create a hardware platform for rapid imaging and in-human
diagnostic 13C MRSI, the primary outcomes for this work will be analysis of prototype and
simulation quality in comparison to that of current ERC technology. As an ethical constraint,
all design criteria must be met without increasing the size of the current ERC.
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4.2 Prototype Design and Simulation Results
To design and build a receive-only proton- and carbon-sensitive endorectal coil to provide
increased SNR and imaging acceleration by optimizing element geometry to the shape of the
prostate, we will need to prove that geometry developed in this proposal better matches the
anatomy of the prostate than current designs to improve SNR. We will need to prove that
at least two individual elements in our design have nonsignificant sensitivity profile overlap
to improve acceleration, and that this is not feasible with currently available designs. We
will need to prove that overlapping receive elements in the longitudinal direction is feasible
without the effects of inductive coupling between each element, that signal penetration is
not lost over the area of the prostate gland compared to currently available designs, that the
carbon elements can be decoupled from the proton elements, and that these improvements
are feasible under the ethical constraint of not increasing the size of the ERC for equal
patient comfort.
Experiment 1: determine the expected shape and size of the prostate gland.
Current ERC technology does not discriminate signal reception in the area of the prostate
as it is not tailored to the geometry of the prostate. Instead, it receives non-uniformly from
an area including the prostate. Receiving signal from areas outside the prostate increases
the amount of noise that can map to pixels inside the prostate on resulting images. While
prostate anatomy varies, especially in the diseased state, there are tendencies which we
capitalize on in our design. Prostatic growth is generally a product of the central gland
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(CG), which can grow during the normal aging process due to benign prostatic hyperplasia
(BPH). The CG is largely located in the base of the prostate, thins in the midgland and is
absent in the apex. The peripheral zone (PZ) is present surrounding the CG in the base and
midgland, and is prominent in the apex. While prostate cancer frequently occurs in the PZ,
it is rare in the exams seen at our institution for the PZ to measurably increase in size due
to prostate cancer. For this reason, an ERC designed to match the anatomy of healthy and
diseased prostate glands should equal the width of current ERCs at the base and midgland
of the prostate to accommodate the CG, and taper towards the apex as gland size decreases.
This will decrease the amount of signal acquired from tissues surrounding the prostate gland
towards the apex while preserving full size towards the base. To validate this hypothesis
in a preliminary data set, prostate volume traces from our institution on 8 patients showed
a base wider in oblique R/L than towards the apex. An example of this trace is shown in
Figure 4.1.
From this preliminary experiment:
Prostate Width(mm) =
Base
Midgland
∼= 0.93± 0.116 Apex
Midgland
∼= 0.66± 0.067 (4.1)
A power analysis will determine whether this preliminary observation holds for the variety of
glands seen at our institution, using the mean and standard deviation from the preliminary
data, the noncentrality parameter φ determines the number of samples required to prove the
preliminary observation.
To Prove :
Base
Midgland
= 0.93(φ = 0.55)
Apex
Midgland
= 0.66(φ = 0.76) (4.2)
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Figure 4.1: In an example patient, we see the base of the prostate is noticeably wider than
the apex of the prostate.
To validate this finding, 40 prostates from recent patients at our institution will be
segmented and mean width in the base, midgland, and apex will be recorded. The robust
commercial software system DynaCAD (Invivo, c©2013) will be used for segmentation. From
this, a 3D volume of the prostate will be determined.
Experiment 2: determine the limits of array design based on inductive coupling.
All current ERCs developed with multiple receive elements have two overlapping receive
elements, leading to similar sensitivities along the overlap, which underdetermines the matrix
combination at the heart of parallel imaging. To prove that at least two elements in our
design have no sensitivity profile overlap, we will include three elements in our design. A
large center element will receive from the midgland of the prostate, and a small element
longitudinally overlapping with the center element will receive from the base and apex of
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Figure 4.2: A Proposed 3-element coil design, including a shortened center coil (blue),
a wide base coil (green), and a narrow apex coil (yellow), and B starting dimensions for
individual coil sizes, to be iteratively altered based on optimal coil overlap, while tapering
towards the apex in alignment with the gland.
the prostate, respectively, as shown in Figure 4.2.
Although the center element will overlap with both the base and apex elements, the
base and apex elements will have minimally-overlapping sensitivity profiles, increasing the
potential imaging acceleration. A simulation, shown in Figure 4.3, illustrates the magnetic
field induced by the base and apex coils, with little overlap. Because the center coil signal
covers the area between base and apex coils, at least two elements will provide signal at all
points in the prostate. Determining whether this signal contribution is significant will depend
on the iterative size specifications from Experiment 1. This simulation can be repeated with
successive designs.
These encouraging simulation results prompted a prototype to prove lack of coupling on
the bench. A solid copper wire prototype was developed to resonate at the proton frequency
with elements matching the size and shape of the model in Figure 4.2, to determine that
overlapping elements in the longitudinal direction is feasible at the proposed dimensions
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Figure 4.3: Minimal overlap between magnetic fields generated from the base and apex
elements (blue) over the length of the coil (green). Note, for this simulation, the magnetic
field generated from the center element is not shown.
without the effects of inductive coupling. Using a network analyzer to measure S11 (reflection
coefficient) by a single-loop sniffer, the elements—once tuned to 128 MHz—were overlapped
so that no inductive coupling was present between adjacent elements. The center element
was then removed, to ensure no inductive coupling existed between nonadjacent base and
apex elements. Overlaid on a ruler in Figure 4.4, we can see that the optimal overlap to
negate adjacent inductive coupling extends the coil elements 3mm past the current ERC
length of 8 cm. Because an ethical constraint of this project is not increasing the size of the
ERC, the center element size will be iteratively shortened to ensure no inductive coupling
while keeping within size limitations.
One limitation of this prototype is the use of lumped capacitors, which inherently change
the impedance at different locations along an element. The significant lowering in frequency
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for reception of 13C changes the relationship between capacitance and inductance and cal-
culation of Q, which relates component values to coil performance and SNR at a range of
frequencies given in Eqn 4.3:
Q =
f
∆f
=
Xp
Rp
where Xp = j2pifL =
1
j2pifC
(4.3)
Where f is the resonant frequency of the coil, Δf is the bandwidth of frequencies received by
the coil, Rp is the impedance of the coil, which is 50 ohms, and Xp is the reactance in the
coil, which is a function of inductive and capacitive loading in the coil. For 13C-MRSI, Δf
must be greater than 5000 Hz to receive from necessary metabolites.
For the proton-sensitive elements, the inductance in the wire is sufficient to resonate at
128 MHz with capacitance in the range of 9 to 14pF—capacitance increases with decreasing
element size because length of wire is proportional to inductance. A much higher capacitance
is needed to resonate similarly-sized elements at 32 MHz for 13C reception, which will decrease
Q, increasing the range of acceptable bandwidth for signal reception. To more accurately
distribute the capacitance without introducing lumped inductors, capacitors in the range of
60-140pF will be needed.
Experiment 3: prove that the signal penetration is similar over the area of the prostate in
comparison to current ERC designs.
A study of 847 recent prostate exams at our institution was performed to assess the maximal
extent of prostate glands in the R/L and oblique A/P directions, with results summarized
in Table 4.1. Maximal extent information was obtained from the CSI voxel size of 1H-MRSI
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Figure 4.4: Solid copper prototype with lumped capacitors used to assess inductive coupling
between adjacent and nonadjacent elements shows no inductive coupling between base and
apex coils, and inductive coupling between adjacent elements mitigated by overlap.
in recent exams, which is manually altered by the technologist to align with the edges of
the prostate in R/L and oblique A/P. The MatLab simulation introduced in Experiment 2
(Figure 4.3) was expanded to include full magnetic field maps from the proposed coil as well
as a model of the current single-loop ERC, shown in Figure 4.5.
We see from Table 4.1 that the maximal size documented in recent prostate exams in
R/L is 8 cm. However, in the simulation in Figure 4.5 we see the traditional ERC extending
12-14 cm in R/L, picking up unnecessary signal from outside the prostate gland. This effect
is diminished in our proposed design, which extends less than 10cm in R/L. We also see
from Table 4.1 that the maximal size in A/P is 7.24 cm, but the 95th percentile is 4.71
cm. Penetration in A/P is difficult for the small element sizes necessary for comfortable
ERCs, but less than 5% of prostates extend further than 4.71 cm in A/P. We see that the
proposed design performs similarly to the traditional ERC in A/P penetration. However, this
preliminary experiment doesn’t distinguish the largest extent of the prostate from differences
between the base, midgland, and apex. To adequately answer the question to whether the
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Table 4.1: Size ranges of prostates examined at our institution, n=847. Data collected
based on the prescription volume acquired during 1H-MRSI imaging, wherein prescription
volume is tight around the prostate, excluding the surrounding lipid and rectum.
Prostate Sizes R/L (cm) A/P (cm)
Minimum 2.37 1.78
5th % 4.19 2.28
25th % 4.92 2.86
Mean 5.40 3.39
Median 5.38 3.30
75th % 5.89 3.85
95th % 6.69 4.71
Maximum 8.06 7.24
Figure 4.5: 2D views from MatLab simulations showing signal penetration in R/L and
A/P for (left) the current single-loop ERC and (right) the proposed ERC design.
proposed design loses signal over the area of the prostate, the model created by averaging
prostate shapes in Experiment 1 will be overlaid on the simulated magnetic field maps, and
the magnetic field will be measured throughout the average gland. This will be repeated for
the 95th percentile prostate size and shape.
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Experiment 4: assess and mitigate coupling between carbon and proton coils.
Because the proton frequency, ∼128 MHz, is close to the fourth harmonic of the carbon
frequency, ∼32 MHz, at 3T, signal from proton reception has the capability to induce current
in the carbon-sensitive elements. To protect from coupled currents in the 13C coil shifting
the resonant frequency and decreasing the SNR of the proton coil, an LC trap circuit can
create an effective open circuit in the 13C coil triggered at the proton frequency. Without
current flow, the circuit will not generate a received electric signal. It may similarly be
necessary to include trap circuits tuned to the carbon frequency on the proton coils. However,
trap circuits present additional lumped circuitry and therefore resistance and potential for
component failure.
Decoupling is not always necessary depending on distance and signal strength, so trap
circuits will be planned but not included in simulation. Instead, once geometry and position
of elements are settled in Experiments 1-4, a prototype will be built with proton- and carbon-
sensitive elements. Current will be induced in each of the proton-sensitive elements and a
network analyzer measuring S21 (forward voltage) will detect induced current in each carbon-
sensitive element. Induced current in any carbon-sensitive element from any proton-sensitive
element will trigger the need for a trap circuit. This experiment will be repeated to detect
induced current in each proton-sensitive element from each carbon-sensitive element, and
necessary trap circuits will be included.
81
4.3 Future Directions
With an ERC using multiple elements at the proton and carbon frequencies, every 3D se-
quence in the mpMRI of the prostate can be shortened. However, optimal conditions for
acceleration will vary between the sequences and will therefore require extensive testing. As
an example, it may be more optimal for data collection to utilize the time saved in DCE to
acquire additional slices than are currently available, or it may be more valuable to increase
spatial resolution in 3D anatomic imaging to facilitate reconstruction to the coronal and
sagittal planes.
Early-phase clinical trials on hyperpolarized 13C-MRSI efficacy in human prostate can-
cer are ongoing at our institution. Utilization of this coil in conjunction with these trials
would provide the means of testing in-human performance in carbon-sensitive imaging and
the limits of practical acceleration and therefore, spatial resolution. These clinical trials
include patients intending to undergo radical prostatectomy, meaning performance versus
the currently-available ERC can be tested using whole-mount pathology as a gold standard.
As a final direction, it is desirable to create the most comfortable probe. Using an
inflatable balloon probe to house the ERC could increase patient comfort, and therefore
patient compliance in completing the mpMRI. Options including flexible braided wires and
printed circuit boards on flexible materials should be explored for application in the proposed
design.
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Chapter 5
The Rate of Hyperpolarized
[1-13C]Pyruvate to [1-13C]Lactate
Conversion Distinguishes High-Grade
from Low-Grade Prostate Cancer in
Patients
Abstract
There is a pressing clinical need to distinguish aggressive cancers from indolent cancers in
the prostate to avoid diminishing quality-of-life and costly overtreatment. In this work,
we present results from a phase 2 clinical trial of hyperpolarized [1-13C]pyruvate magnetic
resonance imaging, and quantitatively measure real-time metabolomics in prostate can-
cers and regions of benign tissue. Twenty-three patients underwent a 3T multiparametric
1H/13C MRI of the prostate followed by radical prostatectomy and whole-mount pathologi-
cal grading. Carbon imaging parameters of overall lactate (AUCLac), lactate/pyruvate ratio
(AUCLac/Pyr), and the modeled rate of flux from pyruvate to lactate, (kPL), were measured
in eighteen high-grade lesions, thirteen low-grade lesions, and twenty-three benign regions.
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Mixed linear models characterized differences between tissue types while controlling for data
partially-paired by patient. Low-grade cancers had significantly higher values of all carbon
metrics compared to benign regions (AUCLac, AUCLac/Pyr, and kPL). While AUCLac was not
significantly higher in high-grade disease, there was a significant difference in AUCLac/Pyr
(p<0.025), and a strongly significant difference in the kPL (p<0.0005). This study demon-
strated for the first time that kPL is significantly elevated in high-grade prostate cancer
versus both benign prostate tissue and low-grade disease, consistent with prior pre-clinical
studies.
5.1 Introduction
While 164,690 men were estimated to be diagnosed with prostate cancer in the United States
in 2018, only 18% (≈ 29,430) of these patients will have aggressive disease resulting in death
from prostate cancer [128]. Due to increased screening using serum prostate specific anti-
gen (PSA) and extended-template TRUS-guided biopsies, patients with prostate cancer are
being identified at an earlier and potentially more treatable stage. Despite a sharp fall in
mortality since the start of the PSA-based early detection era in the US [128], prostate can-
cer early detection efforts have become controversial [129] [130], in part due to high rates
of diagnosis and over-treatment of low-risk, indolent tumors, many of which would likely
never have caused symptoms or loss of life had they remained undiagnosed. All treatments
entail potential adverse effects on long-term quality of life (QOL) (e.g. erectile dysfunction,
incontinence) [131] and for those with indolent disease, these effects come without the ben-
efit of improved life expectancy. While those with indolent tumors can be managed with
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active surveillance, approximately 30% of these patients will be reclassified as higher risk
for disease progression, requiring definitive therapy [132] [133]. The aggressiveness of indi-
vidual tumors cannot be predicted with great confidence using currently available clinical
and imaging prognostic data. Current clinico-pathological variables including PSA levels,
biopsy characteristics (grade and volume of disease), and stage of disease all provide impor-
tant insight into disease risk [134], but unfortunately fail in discriminating aggressive versus
indolent disease in many patients. The current state-of-the-art for imaging localized prostate
cancer, multiparametric 1H MRI, has demonstrated the ability to localize tumors for subse-
quent biopsy and treatment, but cannot consistently grade tumor aggressiveness accurately
in individual patients [135]. There is an unmet clinical need for an accurate, non-invasive
imaging method to detect aggressive, clinically significant cancer early in these patients so
timely treatment of this potentially deadly metastatic disease can be initiated.
There is growing evidence that the ability of cancer cells to invade adjacent normal tissues
and locally grow and metastasize to distant sites is significantly impacted by changes in
tumor cellular metabolism [136]. Specifically, the Warburg effect, an up-regulation of aerobic
glycolysis and production of lactate, the result of the lactate dehydrogenase (LDH) reaction,
is an adaptation of cancer cells that aids in survival, growth, and metastases to a lethal
phenotype [136]. Lactate dehydrogenase-A (LDHA), a protein subunit of the highly lactate-
favoring LDH isoform muscle-type 5 (LDH-5), catalyzes the reduction of pyruvate to lactate
and is overexpressed in many cancers, including prostate tumors [137] [138]. The Warburg
effect is increased in prostate cancer due to key genomic changes that directly upregulate
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LDHA expression: loss of the PTEN (phosphatase and tensin homolog) locus, leading to
activation of the PI3K/AKT pathway in 70% of prostate cancers; and 8q amplification,
including amplification of the Myc gene, which occurs in 30% of prostate cancers [139].
Hyperpolarized 13C magnetic resonance spectroscopic imaging (HP 13C MRSI) is a pow-
erful new metabolic imaging method which uses specialized instrumentation to provide
signal enhancements of over 10,000-fold using enriched, safe, endogenous, non-radioactive
compounds [79]. While prostate cancer is often inadequately evaluated using FDG-PET
(fluorodeoxyglucose-positron emission tomography); which assesses glucose uptake and phos-
phorylation [140] [141], HP 13C MRSI detects down-stream metabolism, specifically the
metabolic shift of prostate cancer cells from producing and secreting citrate to producing
lactate [142] [143]. In a phase 1 clinical trial of HP [1-13C]pyruvate MRSI, the metabolic
rate of conversion of HP 13C-pyruvate to 13C-lactate, (kPL), was shown to be significantly
increased in regions of prostate cancer [80], however this clinical trial involved patients who
did not receive surgery, therefore correlation of kPL with pathologic grade was not possible.
In this manuscript we present the first patient data demonstrating the ability of kPL to
detect aggressive, high-grade (>20% Gleason pattern 4 disease) prostate cancer. A 3D dy-
namic hyperpolarized 13C MRSI [82] / multiparametric 1H MRI approach [115] was utilized
to determine the kPL associated with benign prostate tissue, low- and high-grade prostate
cancer using whole-mount step section histopathology after surgery as the standard of ref-
erence.
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5.2 Materials and Methods
This study was approved by the Committee on Human Research at this institution and was
compliant with the Health Insurance Portability and Accountability Act. Written, informed
consent was obtained from 23 subjects enrolled in a clinical trial entitled “A pilot study of
magnetic resonance (MR) imaging with hyperpolarized pyruvate (13C) to detect high-grade
localized prostate cancer” (NCT02526368). Patients received a 3D dynamic hyperpolarized
13CMRSI / multiparametric 1HMRI exam acquired on a 3TMRI (GE Healthcare, Waukesha
WI, USA) using a dual-tuned 1H/13C endorectal coil [144] in combination with a 4-channel
1H pelvic array for reception and a 13C Helmholtz configuration “clamshell” coil for 13C
excitation. Patients were instructed to eat a light diet for 24 hours before the exam and to
perform a FLEET enema 1-3 hours before the exam.
A solution of 0.43 mL/kg [1-13C]pyruvate was polarized for 120-210 minutes in a 5T
SPINLabTM hyperpolarizer (GE Healthcare, Waukesha WI, USA) and injected at a flow
rate of 2 mL/s before a 20 mL saline flush. Sufficient EPA filtration and physiologic pH were
confirmed by a pharmacist before injection.
Anatomic imaging was performed using a T2-weighted fast spin-echo sequence with FOV
= 18 cm, slice thickness = 3mm, matrix = 512 x 512, and TR/TE = 6000/96, prescribed at
an obliquity matching the posterior edge of the prostate. Anatomic images were intensity-
corrected for the endorectal coil profile [19].
Functional imaging (DWI and DCE MRI) was performed at the same obliquity and slice
thickness as the anatomical T2-weighted sequence. Six-direction diffusion-weighted imaging
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(DWI) was acquired using a 2D single shot spin-echo sequence with a b-value of 600 s/mm2,
FOV = 18 cm, TR/TE = 4000/(minimum full TE) ms, slice thickness = 3mm. Additionally,
a high b-value DWI was acquired using a 2D single shot spin-echo sequence with a b-value of
1350 s/mm2, FOV = 26 cm, TR/TE = 4000/(minimum full TE) ms, slice thickness = 3mm.
DCE MRI was acquired using a single dose of gadopentatate dimeglumine (Magnavist, Bayer
Inc.) injected at 2 mm/sec with total injected amount determined by patient body weight.
DCE MRI used a 3D fast SPGR sequence with a temporal resolution of 10.4 s, FOV = 46
cm, TR/TE = 3.5/0.9 ms, flip angle = 5◦, with 5 timepoints acquired before injection to
establish a baseline for semi-quantitative metrics.
The MR scanner was calibrated to the carbon frequency immediately before dissolu-
tion, based on signal from a 660 µL of 8 M 13C-urea standard embedded in the endorectal
coil. 3D dynamic carbon imaging was performed using a dualband spectral-spatial pulse
sequence with a variable flip angle to conserve non-replenishing SNR, followed by an echo-
planar spectroscopic imaging (EPSI) readout with compressed sensing in both the spatial
and temporal dimensions for a total 288-fold acceleration over full-sampled conventional
spectroscopic imaging [82]. This acquisition scheme covers the entire prostate with 8mm3
resolution and 2 s temporal resolution over 21 timepoints.
Hyperpolarized carbon data were reconstructed using an in-house MATLAB routine [145].
After accounting for frequency drift due to transmit field heterogeneity, the pyruvate and
lactate signal at each timepoint was measured as the integrated area under the curve of
the real component of a phase-corrected spectrum. The exam noise was calculated as the
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pyruvate signal in next-to-edge slices in the first timepoint of acquisition, presumably before
the pyruvate bolus.
Image maps of the total area under the curve over time of pyruvate (AUCPyr) and
lactate (AUCLac) were intensity-corrected for the endorectal receive coil profile [19]. A
Lactate/Pyruvate AUC Ratio map (AUCLac/Pyr) was created as a ratiometric surrogate for
metabolic conversion, and an uncorrected SNRPyr map based on the AUCPyr and calculated
exam noise was used as a check on voxel quality:
SNRPyr =
AUCPyr
σ(noise)
(5.1)
An inputless, two-compartment kinetic model was built to measure the pyruvate-to-
lactate conversion rate, kPL [146]. The two-site exchange model accounts for uni-directional
conversion of pyruvate to lactate, signal loss due to serial RF excitations, and the spin-lattice
relaxation (T1) of pyruvate and lactate. At each timepoint, the available pyruvate magneti-
zation serves as the input function, and the available pyruvate and estimated lactate at the
previous timepoint are used to estimate the available lactate. A hybrid discrete-continuous
model accounts for the variable flip angle acquisition scheme by using the magnetization
immediately prior to each RF pulse to compute the magnetization available after each RF
pulse [147]. Confidence intervals and a coefficient of determination for each kPL measure-
ment based on the nonlinear least-squares curve-fitting between true and modeled lactate
were also mapped for quality control during ROI analysis.
After radical prostatectomy, whole-mount resections were sliced at 3mm resolution to
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match T2-weighted imaging, and regions of cancerous and noncancerous tissue were labeled
by Gleason score and percent cancer by a licensed pathologist. Regions-of-Interest (ROIs)
were manually translated from whole-mount pathology onto high-resolution T2-weighted im-
ages, and propagated to image maps of carbon metrics after 3D rigid registration based on
a urea phantom embedded in the endorectal coil and nearest-neighbor interpolation to the
high-resolution T2-weighted image.
A variety of checks were implemented to control the quality of carbon data analyzed in
this clinical trial. Carbon image maps were sinc-interpolated by 2, and only voxels with
25% area or more in the ROI were included in the analysis of that ROI. Additionally, only
voxels with an SNRPyr over 105, (an average SNRpyr of 5 per timepoint over 21 timepoints),
were included. Voxels with proportionally large confidence intervals or low coefficients of
determination were determined to have poor fit quality, and were excluded from analysis.
The maximum value of each carbon parameter in an ROI was used to represent the
region, similar to injected agents used in PET imaging [148]. For regions spanning ROIs on
multiple slices, the overall grade was calculated based on the size, percent cancerous tissue,
and percent Gleason grade of each ROI on each slice. Cancerous lesions with 20% Gleason
pattern 4 disease or higher were considered high-grade, aggressive cancers in this study.
Differences in metabolism between benign tissue and low-grade cancers, and between low-
grade and high-grade cancers were characterized by mixed linear effects analyses to account
for data partially-paired by patient and Bonferroni corrected for multiple comparisons. Sig-
nificance was determined by likelihood ratio tests between models with a fixed effect of cancer
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grade and models without. To evaluate the ability of kPL to predict aggressive prostate can-
cer, kPL values were normalized to the region of normal tissue for each patient, and ROC
analyses were performed and compared to the predictive ability of mean water ADC and
a linear combination of kPL (normalized to benign tissue) and mean ADC. Statistics were
performed in python (Python Software Foundation, Python Language Reference, version 3)
and R (R, Inc., Boston, MA c© 2016).
5.3 Results
Twenty-three patients underwent a multiparametric MRI with 13C-MRSI at our institution.
Patients presented at an average 66 ± 7.5 years of age, with an average PSA of 8.4 ± 5.2
ng/mL. Seventeen patients presented with a PI-RADS score of 5, 4 patients presented with a
PI-RADS score of 4, and 2 patients presented with a PI-RADS score of 3 based on a clinical
mpMRI. The clinical information of all patients is summarized in Table 5.1.
The average time to injection for [1-13C]pyruvate in this patient cohort was 62.3s (range
49 to 83s); injection time was 67.6s, (range 43 to 88s), in the phase 1 trial (18). The injection
had an average volume of 34 ± 3.0 mL, an average pyruvate concentration of 237 ± 11.4
mM, and a 13C polarization of 38 ± 6.0% (17.8 ± 3% polarization was obtained in the phase
1 trial [80]). From these twenty-three patients, eighteen high-grade tumors, thirteen low-
grade tumors and twenty-three regions of non-cancerous tissue—one in each patient—were
identified.
A representative patient with high-grade prostate cancer is shown in Figure 5.1. A
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Gleason 4+5 lesion was observed in the right posterior aspect of the peripheral zone extending
from the apex through the base of the prostate on whole-mount step section pathology. The
corresponding T2-weighted and ADC image demonstrates a clear region of reduced T2 signal
intensity and ADC (ADC = 1327 ± 342 10−3 mm2/s) in the same location as the region of
the Gleason 4+5 pathologic lesion. Based on the mpMRI findings, this lesion was given a
PI-RADS score of 5. Correspondingly there was an elevation of kPL (0.0052 ± 0.0019 s−1)
which was clearly visualized on the T2-weighted images overlaid with a map of normalized
kPL in the same spatial location as the ADC and pathologic abnormalities, with a kPL within
the lesion of 275% that of the normal tissue in this patient. Interestingly, there was a great
deal of heterogeneity in ADC and kPL across this large high-grade lesion and the region of
lowest ADC did not correlate with the region of highest kPL.
A representative patient with low-grade prostate cancer is shown in Figure 5.2. A Gleason
3+3 lesion was observed in the right posterior midgland close to the midline on whole-mount
step section pathology. The corresponding T2-weighted and ADC images demonstrated a
region of reduced T2 signal intensity and ADC (ADC = 1439 ± 165 10−3 mm2/s) in the same
location as the region of the Gleason 3+3 pathologic lesion. The magnitude of reduction in
T2 signal intensity and water ADC were less than the high-grade patient’s tumor in Figure
5.1, consistent with low-grade disease, however this lesion was still clear enough to be given
a PI-RADS score of 4. There was a corresponding elevation of kPL (0.0104 ± 0.0019 s−1)
which was clearly visualized on the T2-weighted images overlaid with a map of normalized
kPL in the same spatial location as the ADC and pathologic abnormalities, with a kPL in
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Table 5.1: Clinical presentation of 23 patients after multiparametric MRI of the prostate
and radical prostatectomy with whole-mount resection.
Age High-Grade Lesion Low-Grade Lesion PSA ECE PNI SVI
70 G4+4 G3+4 26.2 Yes Yes No
60 G4+3 G3+3 7.32 Yes Yes No
60 G3+4 5.01 Yes Yes No
74 G4+4 G3+3 3.71 No Yes No
77 G5+4 16.3 Yes Yes Yes
75 G4+3 1.13 No Yes No
70 G5+4 7.31 Yes Yes Yes
67 G4+4 G3+3 7.35 No Yes No
53 G3+3 6.32 No Yes No
71 G5+4 8.62 Yes Yes No
55 G3+3 7.22 Yes Yes No
56 G3+4 7.96 Yes Yes No
70 G3+4 4.80 Yes Yes No
56 G4+3 G3+3 10.9 No No No
65 G4+3 G3+3 6.47 Yes Yes No
73 G5+4 5.62 Yes Yes Yes
66 G5+4 G3+4 12.1 Yes Yes No
78 G5+4 7.49 Yes Yes Yes
62 G4+3 G3+3 4.20 Yes Yes Yes
73 G4+3 12.6 Yes Yes No
61 G4+3 12.9 Yes Yes No
59 G4+3 4.19 No Yes No
68 G4+5 7.12 Yes Yes Yes
the lesion of 140% that of the normal tissue in this patient. The kPL across this smaller
low-grade tumor was more homogenous than in the high-grade tumor.
A summary of the maximum AUCLac, AUCLac/Pyr, and kPL values in benign tissue,
low-grade prostate cancers, and high-grade prostate cancers, is provided in Table 5.2 and
Figure 5.3. The maximum value in each HP carbon parameter, AUCLac, AUCLac/Pyr, and
kPL, increased from benign to low-grade cancer and from low-grade to high-grade cancer.
AUCLac was the most variable carbon metric for all three tissue types (benign, low- and
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Figure 5.1: A 68-year-old patient with a PSA of 7.12 ng/mL, Gleason 4+5 prostate cancer
in the left peripheral zone from base to apex (pT3bN1, ECE, SVI) at step section pathology
(A) after surgery, PI-RADS 5 on mpMRI, kPL = 275% of normal. The B ADC map
clearly shows the region of tumor, and C the normalized kPL maps overlaid on T2-weighted
images showed a region of elevated kPL over the lesion identified by ADC and whole-mount
pathology.
high-grade cancer), and was significantly elevated in low-grade cancer relative to benign
prostate tissues but not between low- and high-grade disease. AUCLac/Pyr and kPL both
demonstrated significant increases from benign prostate tissue to low-grade prostate cancer
and between low- and high-grade disease. The maximum AUCLac/Pyr was 61 ± 22% higher
in low-grade cancer relative to benign tissue (p ≤ 0.0005), and 27 ± 34% higher in high-
grade relative to low-grade cancers (p ≤ 0.025). The maximum kPL in a region was 63 ±
19% higher in low-grade cancer relative to benign tissue (p ≤ 0.0005), and provided the
best separation of high- and low-grade cancer, 33 ± 16% higher in high-grade disease (p ≤
0.0005).
Although all of the tumors investigated using HP [1-13C]pyruvate MRI in this study were
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Figure 5.2: A 53-year-old patient with a PSA of 6.32ng/mL, and Gleason 3+3 prostate
cancer in the right peripheral zone of the midgland (pT2bN0) at step section pathology A
after surgery, PI-RADS score of 4 on mpMRI, and a kPL 140% of normal. The B ADC
map shows diffusely reduced ADC consistent with low-grade disease, and the C normalized
kPL map overlaid on a T2-weighted image shows moderately increased kPL over the lesion
identified by ADC and whole-mount pathology.
Table 5.2: Means and standard deviations of carbon parameters in 23 normal peripheral
zone, 13 low-grade, and 18 high-grade prostate cancers.
Significantly different between benign and low-grade cancer: ‘†’ 0.025 ‘†††’ 0.0005
Significantly different between low- and high-grade cancer: ‘∗’ 0.025 ‘∗ ∗ ∗’ 0.0005
Carbon Parameter Tissue Type
Mean ± Normal Low-Grade High-Grade
Std. Dev. Peripheral Zone Prostate Cancers Prostate Cancers
AUCLac 59.32 ± 40.70 a.u. 96.10 ± 59.92 † 116.7 ± 82.55
AUCLac/Pyr 0.245 ± 0.110 0.388 ± 0.144 ††† 0.453 ± 0.285 ∗
kPL 0.0082 ± 0.0029 s−1 0.0134 ± 0.0049 ††† 0.0165 ± 0.0102 ∗ ∗ ∗
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Figure 5.3: Box plot of the maximum values of carbon parameters; A AUCLac, B
AUCLac/Pyr, and C kPL for 23 benign prostate tissues, 13 low- and 18 high-grade prostate
tumors.
identified by 1H mMRI, there were several cases in which there were spatial mismatches in
maximum kPL and low ADC. There were also several cases in which small volume Gleason
3+3 tumors were missed by both mpMRI and HP [1-13C]pyruvate MRI. A representative
example of both these scenarios is shown in Figure 5.4. While both the ADC map and the
kPL map overlaying the T2-weighted image identify bilateral disease in Figure 5.4, the mean
ADC in the Gleason 3+4 lesion was 1011 10−3 mm2/s, much lower than the mean ADC
of 1360 10−3 mm2/s in the Gleason 5+4 lesion. The smaller, more aggressive Gleason 5+4
lesion had a higher maximum kPL of 0.023 s
−1, 423% of benign prostate tissue as compared
to the G3+4 lesion which had a maximum kPL of 0.016 s
−1, 284% of benign tissue. The
small, anterior Gleason 3+3 lesion was not determined to be abnormal on either ADC or
kPL.
Two of the three tumors with an equivocal PI-RADS score of 3 were found in the same
patient, a Gleason 3+3 and a Gleason 4+3 lesion, but this patient presented with extra-
capsular extension and perineural invasion. The other PI-RADS 3 lesion was identified as
Gleason 4+3 on whole-mount pathology. While these three tumors had the same PI-RADS
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Figure 5.4: A 70 year old patient with a PSA of 7.31 ng/mL, and multifocal prostate
cancer at whole-mount step-section pathology after surgery A; Gleason 5+4 (50% Gleason
5) in the left posterior midgland, Gleason 3+4 cancer (40% Gleason 4) in the right posterior
midgland and Gleason 3+3 in the right anterior midgland, with a surgical stage of pT2bN0.
Water ADC B had the most dramatic reduction in the G3+4 tumor while C kPL was the
most elevated in the G5+4 tumor.
scores, they had dramatically different maximum kPL, values (0.0127, 0.0159 and 0.0184
s−1), and the kPL values were higher than the average maximum kPL value in low-grade
cancers.
Both the maximum, normalized kPL and the mean ADC predicted aggressive disease
in this cohort of patient with an overall area under the ROC of 0.68, and combining kPL
and ADC yields an area under the ROC of 0.75. The difference in sensitivity and speci-
ficity between ADC and kPL ROC curves suggest that these imaging parameters provide
complementary information.
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Figure 5.5: ROC analyses; A mean ADC, B normalized maximum kPL , and C combined
mean ADC and normalized maximum kPL.
5.4 Discussion
A pressing need facing the clinical management of prostate cancer patients is an accurate
imaging method for distinguishing aggressive, high-grade prostate cancer from indolent dis-
ease at the time of diagnosis. Current standard-of-care prostate cancer 1H multiparametric
MRI includes T2- and diffusion-weighted imaging and dynamic contrast-enhanced sequences,
interpreted using the PI-RADS framework [149] [150] [151]. This method is highly effective
in detecting and localizating prostate cancer for subsequent biopsy, but is limited by poor
detection of small volumes of high-grade disease, and the inability to reliably grade lesions
based on imaging parameters [135] [152] [153] [154]. High- spatial and temporal resolution
3D dynamic hyperpolarized 13C MRSI has previously demonstrated the ability to correlate
the rate of hyperpolarized (HP) [1-13C]pyruvate to [1-13C]lactate conversion, kPL, with the
pathologic grade of prostate cancer in a murine model [155]. A phase 1 clinical trial of
HP [1-13C]pyruvate (NCT01229618) in biopsy-proven prostate cancer patients demonstrated
both the safety and feasibility of imaging cancer within the prostate, discriminating prostate
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cancer from benign tissue based on significantly elevated kPL obtained from 2D dynamic
13C spectroscopic imaging data, but with only biopsy-based pathology correlations [80]. In
this manuscript, the kPL associated with benign prostate tissue, low-grade (<20% Gleason
pattern 4), and high-grade prostate cancer in patients was determined using whole-mount
step section histopathology after surgery as the standard of reference.
A number of significant technical improvements were implemented in this study relative
to the phase 1 trial, including use of improved strategies and technology for generating ster-
ile hyperpolarized material using a commercial 5T DNP polarizer (SPINlabTM), automated
injection of HP [1-13C]pyruvate, and use of a new 3D-CSI EPSI dynamic hyperpolarized
13C MRSI sequence [82]. These improvements lead to a doubling of the [1-13C]pyruvate
polarization and a 7.8% reduction in HP [1-13C]pyruvate injection time thereby allowing the
acquisition of high spatial and temporal resolution 3D-CSI EPSI with full prostate gland cov-
erage. Using a inputless, two-compartment kinetic model [146] and an appropriate pyruvate
SNR threshold (SNRpyr over 105, an average SNRpyr of 5 per timepoint over 21 timepoints),
kPL maps were robustly calculated, overlaid on the corresponding T2 weighted anatomic
images and correlated with the digitized whole-mount step section pathology providing the
first report of the relationship between kPL and pathologic grade in prostate cancer patients.
In addition, the ability of kPL to discriminate prostate cancer and it’s aggressiveness was
compared to two hyperpolarized carbon parameters (AUCLac and AUCLac/Pyr) that have
been used in prior hyperpolarized 13C MR studies to assess the increased rate of conversion
of HP pyruvate to [1-13C]lactate associated with prostate cancer presence and progression.
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All three HP carbon parameters investigated in this study, AUCLac, AUCLac/Pyr, and
kPL, increased with the development of prostate cancer and with progression from low- to
high-grade cancer consistent with prior HP [1-13C]pyruvate MR pre-clinical studies [81] [82]
[118]. In this study, AUCLac was the most variable carbon metric for assessing increased
lactate production and was significantly increased in cancer relative to benign prostate but
not between low- and high-grade cancer. Both AUCLac/Pyr and kPL significantly increased
in high- versus low-grade prostate cancer and kPL demonstrated the best discrimination of
high- and low-grade prostate cancer, indicating the benefit of correcting for pyruvate delivery
and modeling the dynamic HP [1-13C]pyruvate data.
Of the mpMRI parameters, water ADC has shown the greatest promise for reflecting
the pathologic grade of prostate cancer, with lower ADC values found in higher Gleason
grade cancers [156] [157] [158] [159]. In this study, kPL and water ADC predicted high-grade
(Gleason score ≥ 4+3) disease in this cohort of patients with the same accuracies (ROC
of 0.68). However, the differences in sensitivity and specificity observed between the ADC
and kPL ROC curves, and the fact that we observed spatial mismatches between lowest
ADC and highest kPL in individual tumors, suggest that these imaging parameters provide
complementary information. Moreover, combining kPL and ADC increased the accuracy of
predicting high-grade disease over either technique alone (ROC of 0.75).
Several limitations of our study are worth mentioning. First, the prostate cancer patient
population studied was heavily weighted towards patients with more advanced disease (Table
5.1), since this is the patient population that currently receive surgery at our institution.
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Specifically, there were only three Gleason 3+3 tumors studied in the low-grade patient
cohort, with the remaining low-grade tumors containing up to 20% Gleason pattern 4. Ad-
ditionally, the Gleason 3+3 tumors studied were associated with more aggressive pathologic
features, i.e., large volume (≥ 0.5cc) disease, adjacent extracapsular extension or perineural
invasion, and high-grade disease in other parts of the gland. A prior published pre-clinical
study indicated a lack of significant increase in the HP Lac/Pyr ratio (i.e., the Warburg
effect) in low-grade prostate cancer versus benign prostate tissue, with significance only oc-
curring with progression to aggressive, high-grade disease [118]. This finding is consistent
with prior publications suggesting that the Warburg effect does not become important in
prostate cancer until late-stage/high-grade disease [160] [161] [162] [163]. These publications
argue that early-stage/low-grade (Gleason 3+3) prostate cancers rely on lipids and other bi-
ologic fuels for energy production, and that the glycolytic phenotype is only associated with
the evolution of aggressive disease [164] [165]. Taken together these findings suggest that the
kPL observed for the low-grade tumors in this study are higher, and the difference between
low- and high-grade disease smaller, than what would be expected for a cohort of patients
with truly low-grade/indolent (Gleason 3+3) disease. This hypothesis is being tested in a re-
cently initiated HP [1-13C]pyruvate MRI study of prostate patients with early-stage/indolent
disease selecting or on active “active surveillance” as their clinical management course and
receiving MRI/TRUS fusion biopsy as the pathologic standard of reference (NCT03933670).
Another potential limitation of this study was the spatial resolution of the 3D dynamic
HP MR data acquired (≈ 0.5cc) which could impact kPL and the other HP 13C parameters
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studied due to partial voluming of the region of interest (benign or malignant) with sur-
rounding tissues. Partial volume effects were minimized by using the maximum values of the
HP 13C parameters for analyses, similar to what is done with SUVmax in positron emission
tomography (PET) [148]. Nevertheless, the HP 13C MRI spatial resolution was sufficient for
us to capture significant differences in kPL between benign, low- and high-grade cancer as
well as heterogeneity in kPL within individual lesions. Additionally, advances in HP
13C MRI
imaging technology will reduce the achievable voxel size, and higher resolution (≈ 0.3cc) 3D
HP 13C EPI [166] studies of the human prostate are being implemented.
In conclusion, high spatial and temporal resolution 3D dynamic hyperpolarized [1-13C]pyruvate
MRSI with full prostate coverage can be obtained, and the 3D dynamic data modeled, to
produce maps of the apparent rate of conversion of pyruvate to lactate (kPL). This study
demonstrated for the first time that kPL is significantly elevated in high-grade prostate cancer
versus both benign prostate tissue and low-grade disease, consistent with what was observed
in a prior pre-clinical studies [81] [82] [118] and confirming the observations of the initial
phase 1 clinical trial of HP[1-13C]pyruvate in prostate cancer patients (NCT01229618) [80].
The kPL values determined for benign, low- and high-grade prostate cancer can be used to
design future patient studies to assess the utility of kPL in combination with other multi-
parametric MRI parameters, to best select patients for surveillance or aggressive treatment,
and to quantify early therapeutic response or failure.
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Conclusion
The multiparametric MRI offers unique information to clinicians and patients about the
spread, functionality, and energetics of prostate cancers, however ambiguous disease staging
can lead to unnecessary invasive diagnostic metrics and overtreatment of prostate cancer.
In Chapter 1, we outlined the current state of the art of the multiparametric MRI of the
prostate, with high resolution anatomic imaging in conjunction with functional diffusion-
weighted imaging, dynamic contrast-enhanced MRI (DCE MRI), and proton magnetic res-
onance spectroscopic imaging (1H-MRSI). In Chapter 2, we provided an improvement to
the diffusion-weighted imaging portion of the multiparametric MRI. By limiting the number
of phase encodes, and by using the chemical shift between water and fat to only refocus
the water signal, we can significantly reduce the susceptibility artifact on resulting apparent
diffusion coefficient maps. In Chapter 3, we showed how to use diffusion and DCE MRI to
distinguish chronic inflammation, a common confounder in prostate cancer MRI diagnostics,
from low-grade prostate cancers. In Chapter 4, we conceptualized and simulated a novel
radiofrequency receive coil array to translate hyperpolarized 13C imaging to the clinic. We
showed that a three-element longitudinal design will allow parallel imaging, greatly increas-
ing the amount of available signal during the non-renewable hyperpolarized signal decay
and resulting in a usable clinical resolution for hyperpolarized carbon imaging of the human
prostate. In Chapter 5 we show initial results from the first phase 2 clinical trial of 13C in the
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characterization of prostate cancer aggressiveness, showing a unique ability to quantitatively
measure differences in real-time tissue metabolism. Together, these techniques improve the
precision with which we use the multiparametric MRI to grade prostate cancer, aiding in
the management of clinical patients.
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